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Abstract 
Background Kazakhstan consists of favorable conditions for different vector 
transmitted infectious diseases such as Tick-borne encephalitis 
(TBE) and Crimean Congo hemorrhagic fever (CCHF). Up to 50 
cases of TBE and 10 cases of CCHF are registered annually. Due 
to the lack of diagnostics approaches in remote areas many cases 
remain undiagnosed and the correct case numbers could be higher. 
With this study project I claimed to understand the infection rate of 
TBEV and CCHFV in ticks, to identify the circulating genotypes and 
find out the role of these infections among patients who suffer from 
fever of unknown origin (FUO).  
Methods In six districts of the southern part of Kazakhstan 2341 ticks were 
collected. RNA was extracted from the homogenates and all 
samples were screened for the presence of TBEV and CCHFV by 
real-time reverse transcription (RT-) PCR. Positive samples were 
amplified in conventional RT-PCR using pathogen-specific primers. 
Products of conventional PCR were sequenced using Sanger 
sequencing.  
In two regions the serological and molecular investigation of 
human sera from two pilot regions was conducted. 
Results TBEV RNA was detected in 48 out of 493 investigated tick pools. 
No positive tick pools with CCHFV RNA were detected.  
The picture of serological investigation of human sera among 
patients with fever of unknown origin shows that the antibodies to 
TBEV and CCHFV were detected in serum samples of 18 (2.24%) 
and 102 (12.7%) out 802 tested patients respectively. Molecular 
investigation revealed that CCHFV subtypes Asia1 and reassortant 
Asia1 and Asia2 and Siberian subtype of TBEV circulate. 
Conclusion  For the first time comprehensive data on the prevalence of TBEV 
and CCHF in vectors and among patients with FUO based on 
molecular methods of investigation, the circulating of Siberian 
genotype of TBEV and reassortant of Asia 1 and Asia 2 of CCHFV 
in Kazakhstan were described. The new data will help to improve 
the surveillance system of these infections in Kazakhstan. 
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1 CHAPTER  
1.1 Introduction  
More than 200 conditions could cause fever such as oncology, rheumatology, and 
infections. Of all the conditions the infections remain the main cause. Some causative 
agents as Rickettsia could be a reason of a long term fever, for some viral agents there 
fever duration is short (1). Despite the permanent development of diagnostics facilities, 
the causative agents of fever are not identified completely. The identification of the 
causative agents of fever are very important as fever could be a symptom of a serious 
infection and a sign of an emerging disease. Moreover, a long-term fever has an impact 
on health care cost. Examples of emerging diseases are arboviral diseases as Crimean-
Congo Hemorrhagic Fever (2) and Tick-Borne encephalitis(3). Also, over the last years 
arboviruses were considered to have a significant burden on diseases among humans 
(4) and arboviruses were also considered to be a cause of fever in a certain proportion 
of patients (5). In the recent years arboviruses were also getting attention because   an 
invertebrate arthropod vector is involved in their transmission (6) . 
Within the recent years not only clinical aspects provoke the investigation of 
arboviruses in the territories of Central Asia. The analysis of global emerging pathogens 
showed that the territories of Central Asia have a moderate to high risk for pathogen 
emergence (6). Kazakhstan is one of the biggest countries in Central Asia and it 
borders with Russia, China, Uzbekistan, Turkmenistan and Kyrgyzstan. The population 
of Kazakhstan in 2018 was approximately 18.3 million people (www.forum.kz). Due to 
rapid economic growth, strengthened international business relations, expansion of 
tourism and globalization there is a high demand of knowledge on arboviruses 
circulation, their epidemiology, possible impact on health care and their genotypes (7).  
Kazakhstan has intercontinental climate with a big range of temperature zones. The 
hottest month in Kazakhstan is July, the highest temperature was registered in July +49 
0C in Turkestan oblast (former The South Kazakhstan oblast) and the lowest 
temperature in Akmola oblast -57 0 C in the Central Kazakhstan. The landscape of 
Kazakhstan is varied, desert, semi-deserts, steppes, forests. Hence, the territory of 
Kazakhstan has very favorable conditions for different vectors of zoonotic diseases. 
Northern, Easternбand South-East parts of Kazakhstan are covered with forests area 
goes cross the mountains with enough humidity. The southern parts and western parts 
of Kazakhstan are mostly dry and the only source of water are big rivers. Such different 
landscapes are perfectly matching the preferable conditions of distribution of highly 
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pathogenic agents such as bacteria and viruses (8). Following this, according to reports 
of Kazakh Scientific Center of Zoonotic and Quarantine Diseases (KSCQZD) 40 %-80% 
of territory of Kazakhstan are vulnerable to highly pathogenic bacterial pathogens as 
Yersinia pestis, Francicella tularensis, Bacillus antracis. However, there exist almost no 
data on the prevalence of arboviruses in vectors and their proportion as a causative 
agent among the patients who suffer from fever. But three oblasts (areas) were 
designated as endemic for Crimean-Congo Hemorrhagic Fever and two oblasts (areas) 
are endemic for Tick-borne encephalitis (Atlas) (Figure 1).  
Figure 1. The endemic oblasts (areas) for CCHF and TBE in Kazakhstan 
According to the endemic regions for CCHF and TBE two pilot oblasts were chosen 
for this study: Kyzylorda oblast in the south and Almaty oblast in the south East of 
Kazakhstan. 
Kyzylorda oblast 
Kyzylorda oblast is located east of the Aral Sea in the lower reaches of the Syr Darya 
River, mainly within the Turan lowland (height 50-200 m). The climate of Kyzylorda 
oblast is continental and extremely dry with long hot and dry summer and relatively 
warm, short snowy winter with little precipitation. The average July temperature in the 
north-west is 25.9 ° C, in the south-east it is 28.2 ° C, in January it is 9.8 ° C and 3.5 ° 
C, respectively. The amount of precipitation in the north-west off the coast of the Aral 
Sea is about 100 mm (the smallest amount of precipitation in Kazakhstan), in the south-
east in the foothills of the Karatau up to 175 mm. Kyzylorda oblast consist of 7 districts 
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and two cities Kyzylorda and Baikonur. The population is approximately 753148 people 
(https://e-kyzylorda.gov.kz).  
Almaty oblast 
Almaty Oblast share the borders with Zhambyl Oblast to the west, Karaganda Oblast 
to the northwest (the water border runs along Lake Balkhash), and East Kazakhstan 
Oblast to the northeast. In the east, the region borders with China, in the south with the 
Republic of Kyrgyzstan (Chu and Issyk-Kul regions). Almaty oblast has a complex 
geographic characteristic and a very diverse relief. Almaty oblast is located between the 
ridges of the Northern Tien Shan in the south, Lake Balkhash in the northwest and the 
Ili River in the northeast; in the east Almaty oblast is bordered by China. The entire 
northern part of Almaty oblast is occupied by South Semerechiye plain weakly inclined 
to the north (height 300-500 m), crossed by dry channels - Bakanas, with arrays of ridge 
and loose sand (Sary-Ishikotrau, Taukum). The southern part is occupied by mountain 
ranges up to 5000 m high as Ketmen, Zailiysky Alatau, and Kungei-Alatau. The northern 
part of Almaty oblast is characterized by sharp continental climate, relatively cold winter 
up to –35 ° C, hot summer up to +42 ° C. Precipitations are only 110 mm per year. In 
the foothill zone the climate is mild the precipitation is up to 500-600 mm. The amount of 
rainfall reaches 700–1,000 mm per year. The length of vegetation period in the foothills 
and on the plains is approximately 205–225 days. The north and northwest are almost 
devoid of surface runoff. The only river here is Ili, forming a highly developed marshy 
delta and flowing into the western part of Lake Balkhash. In the south, the foothills of the 
river network are relatively dense; most of the rivers (Kurty, Kaskelenka, Talgar, Esik, 
Turgen, Chilik, Charyn, etc.) originate in the mountains and usually do not reach Ili 
River. In the mountains there are many small fresh lakes (Big Almaty and others) and 
mineral springs Alma-Arasan. Almaty oblast consist of 17 districts. The population of 
Almaty oblast is approximately 2017277 people (http://zhetysu.gov.kz/ru/).  
Ticks and sera were collected from these two pilot oblasts (see Figure 5). 
 Despite the recognized endemic regions for CCHF and TBEV, the Kazakh 
surveillance system on these infections relies on passive population surveillance and 
registering the clinical cases reporting from the health care providers (Hospitals). Due to 
the primitive system of diagnostics based on serological and molecular methods of 
investigation, there is lack of data on the exact prevalence of CCHFV and TBEV in 
vectors and circulating genotype. Serological and molecular methods of investigation 
also need improvement and upgrade to the modern and worldwide used methods. The 
main diagnostic deficiency is not registering the real data on these infections. Also due 
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to the lack or in some regions the absence of diagnostic assays and lack of knowledge 
of medical staff the cases of TBE or CCHF could be remained unrecognized and 
unregistered. According to hospital data, there are many suspicious cases of TBE or 
non- hemorrhagic form of CCHF after tick bites. 
Therefore, a good understanding of the prevalence of CCHFV and TBEV in vectors, 
epidemiology of these infections, possible role of CCHFV and TBEV in a proportion of 
patients who suffer from fever and updating the modern diagnostic assays are need to 
prevent the distribution of these infections in Kazakhstan and surrounded territories. 
Moreover, this knowledge will improve the surveillance and health care system of 
Kazakhstan. The aims of this study are to determine the prevalence of CCHFV and 
TBEV in patients with fever, to assess the demographics associated with fever, to know 
the prevalence of CCHFV and TBEV in vectors of pilot oblasts (areas) and to identify 
the circulating genotypes of these arboviruses. 
The research project was conducted in two directions. First, tick study or investigation 
the prevalence of TBEV and CCHFV in ticks collected in pilot regions. The tick 
collection was conducted at 32 locations of two oblasts (Almaty and Kyzylorda oblasts) 
in May and June in 2015. The second direction of study was serological investigation of 
805 patients with fever to detect the presence of antibodies against the CCHFV and 
TBEV. The blood was collected in pilot regions from April till October 2014-2015, during 
the tick activity. The serological study was also accompanied by epidemiological survey. 
The methods of investigation are outlined in detail bellow. 
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2 CHAPTER  
2.1 Literature review  
2.1.1 Literature review. Tick-borne encephalitis (TBE)  
2.1.1.1 History of TBE 
 Since the early 1930s, in in the Far East of Russian Federation, medical personnel 
faced with severe acute illness with damage to the central nervous system, often ending 
in the death of patients. The disease was completely unexplored. In 1935, 
neuropathologist A.G.Panov, who worked for the Far East, for the first time found that 
this “mysterious” disease is encephalitis. The etiology of this encephalitis was not 
known. But he considered that this encephalitis is already known famous Japanese 
encephalitis. His attempts to investigate the possible etiological pathogen in “the Far 
Eastern Paster” station did not lead to success. It was not only the time of wide 
economic development of the Far East but also the time when the Soviet Union had an 
external threat from militaristic Japan. Manchuria was seized by militaristic Japan and 
developed a plan of military action “OTSU” against the USSR ". Due to this threat, there 
were placed large military units that stood right in the taiga. Among the soldiers, the 
number of patients with unknown neuroinfection was grown. Epidemiological trouble 
could negatively affect the defense capacity of the Far Eastern region(9). People's 
Commissar of Defense Marshal K.E. Voroshilov asked for help the health care ministry 
of the Soviet Union. Therefore, the preparation for an expedition to the Far Eastern 
region is started. The expedition was entrusted to lead the head of the country's first 
medical virologic Laboratory (1935) Professor Lev Zilber. L.A (10). The opportunity to 
select any specialists for the expedition, whom he considered is necessary was given to 
Zilber. Professor Zilber took exclusively the youth and did it quite consciously. He wrote 
later: “Of course, I gathered and warned of the dangers and difficulties or everything 
else but young people have in my eyes a huge advantage. They were not bound by old 
fallacies in regarding this disease ". They planned of investigation of this unknown 
encephalitis that was very successful. The first plan of research was in a case if 
unknown encephalitis is Japon encephalitis, the second plan of research was organized 
for a case if the unknown encephalitis is another encephalitis. And finally, the third plan 
of the research was for a case if the disease is not at all an encephalitis. These plans 
were developed in detail and brought success(11). During this expedition was detected 
the connection between the vector a tick Ixodes persulcatus and illness. During this 
expedition was detected the connection between the vector a tick Ixodes persulcatus 
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and illness. L. Zilber observed the connection, but Chumakov proved it during the 
experiment. This discovery was led into the prophylaxis measurements against the tick 
bites or tick-control measurements. Simultaneously, the young scientists Chumakov, 
Levkovisch, Shubladze, and Soloviev isolated the virus from the cerebrospinal fluid of 
patients suffering from the encephalitis during the acute fever, in average the virus was 
isolated from 29 patients. One of the most achievements of this expedition was not only 
virus identification, but also the description of the clinical presence by a young 
neurologist Shapoval, the description of pathologic changes during the autopsy of 
patients who died from this encephalitis by pathologist Kestner. During the autopsy, 
Kestner identified that the nervous system, especially the brain is susceptible to 
damage. During this expedition, for the first time, the treatment with the immunoglobulin 
was implemented by Shapoval and had a positive outcome in patients. Chumakov could 
get the Immunoglobulin from the convalescence blood serum(12). 
During this expedition was for the first time described the laboratory infections by this 
virus. During the autopsy of the deceased patient, Chumakov M. injured his finger and 
got Tick-borne encephalitis, with severe clinical presence. At the same time, young 
scientists Soloviev V. and Gnevisheva E. were infected by tick-borne encephalitis and 
got a severe infection that affected all their life. Within three months, the expedition is 
started on 15 May in 1937 and finished on 15 August in 1937, the scientists of this 
expedition made a huge discovery in difficult conditions of taiga of Far-Eastern region. 
On 20 August of 1937, the results were reported by Zilber L. and the disease was 
named as spring- summer epidemic encephalitis or tick-borne encephalitis. L.Zilber was 
persecuted for political reasons and sent to prison till 1944. In 1938 the second 
expedition with Pavlovsky as a leader of this expedition was sent to the taiga of Far 
Eastern region. During this expedition, the circulation of the tick-borne encephalitis virus 
and its possible hosts and vectors were investigated, moreover during this expedition 
the first attempts of inactivated vaccine was established. However, some scientists were 
infected during work and died. In 1939 the third expedition, during which the first 
epidemiological experience on the vaccine against the tick-borne encephalitis was 
conducted by Levlovich E. and Dankovskiy N., also the new natural tick-borne 
encephalitis foci were discovered in Ural region and surroundings of the Ural region. 
This expedition also has its victim, during the laboratory work a young parasitologist 
Pomerntsev B., was infected by tick-borne encephalitis virus and died. The fourth 
expedition in 1940 with a scientific leader Levkovich E. was targeted for vaccination the 
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population under the group of risk. The immunization brought its positive outcome as 
decreasing and in some communities the liquidation of morbidity. 
Despite the first strain isolation in 1937 by a group of scientist in the Soviet Union, 
the first reported case and detailed description of the disease consistent with Tick-Borne 
encephalitis virus was made by Schneider in 1931 in Austria(13). He described this 
disease as “meningitis serosa epidemica” of unknown origin and only in 1957 the 
etiology of unknown meningitis was described and identified that it was tick-borne virus. 
And at the beginning of 1973 the first experimental vaccine was ready(14). 
 
2.1.1.2  Microbiology of TBE virus 
 He described this disease as “meningitis serosa epidemica” of unknown origin and 
only in 1957 the etiology of unknown meningitis was described and identified that it was 
tick-borne virus. And at the beginning of 1973 the first experimental vaccine was 
ready(15).The genetic material of the tick-borne encephalitis virus is 11kb single-
stranded positive-sense RNA. The viral RNA consists of one long open reading frame, 
that encodes the mentioned above proteins ( three structural PrM, C, E proteins and 
seven not structural NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5), also 5’ type 1 cup 
and 3’ not coding regions (3’ NCR(16). The 5’ NCR is more conservative in comparison 
with 3’ NCR. 3 ‘non-coding region consists of a conserved region and variable region (V 
3’ NCR) as well (17).  
Based on E sequence and full genome three genetic lineages were distinguished, the 
European, Siberian and Far-Eastern subtypes. However recently this classification was 
reconsidered and now five genetic lineages are distinguished(18). So far, these 
subtypes are European, Siberian, Far-Eastern, Baikalian and Tibetian. Each of them 
has its own geographical distribution  (19). Hence, Far Eastern subtype is mostly 
distributed in regions of the Far East of Russia, China and in some regions of the 
European part of Russia. In contrast, European subtype occurs in countries of Europe, 
in the European part of Russia and very rare in the Far East of Russia. Siberian subtype 
mostly is widespread in the territory of European and Asian part of Russia and very rare 
in European countries (19) (20). The new Baikalian subtype is distributed in the south of 
Eastern Syberia and North Mongolia (15). The Himalayan subtype is distributed in 
China in Qinghai-Tibetian Plateau (17).  
Different subtypes of TBEV are related to different vectors (Ixodidae). 
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2.1.1.3  Clinical presence and treatment of TBE 
The clinical presence of Tick-borne encephalitis is varied from the asymptomatic to 
the heavy clinical manifestation with the involvement and damage of the central nervous 
system. However, according to some authors, most cases of tick-borne encephalitis are 
asymptomatic. The proportion of patients with asymptomatic clinical presence ranges 
between 70-98%(20). The clinical presence of Tick-Borne encephalitis depends on a 
causative subtype. The course of Tick-borne encephalitis could be biphasic in a case 
the disease is caused by a Western type of virus and monophasic febrile illness in a 
case the disease is caused by Far-Eastern type of virus (21). However, this 
distinguishes needs more deep investigation due to the discovery of the new lineages of 
tick-borne encephalitis virus (18). But more authors observed that biphasic course of the 
disease occurs in 75% of all patients who suffer from the tick-borne encephalitis caused 
by European subtype of the tick-borne encephalitis virus. Moreover, it was observed 
that patients with a monophasic course of the diseases in the preponderance of tick-
borne encephalitis cases have the involvement of the central nervous system as 
meningitis, encephalitis and meningoencephalitis as well. And only a not huge 
proportion of such patients have a “febrile headache,” but without the involvement of 
central nervous system, in literature, it is also known as an “abortive form” of the 
disease(22)(23). So, there is a distinguishing of tick-borne encephalitis according to the 
clinical manifestation as asymptomatic infection in 70- 98 % cases of tick-borne 
encephalitis and symptomatic infection as well. Symptomatic infection occurs in all age 
groups (22) 
After the incubation period, that is lasting approximately between four and 28 days, 
but on average up to 10 days (20).The first stage of the disease is presented; it is also 
called as the initial phase of the disease. This stage is characterized by the common 
symptoms of intoxication and not specific symptoms as muscle pain, headache, fatigue, 
weakness. During this stage, the temperature is lasting on average up to 7 days. This 
stage of clinical manifestation is presented only with no specific symptoms and without 
the involvement of the central nervous system(23). The blood picture could have some 
changes. Due to the immune system of organism faces with viremia during the initial 
phase of tick-borne encephalitis, in the blood picture as leukopenia, thrombocytopenia 
alteration could be detected. (24). The initial phase could be abrupted on this phase but 
could develop into the second febrile phase. But the second febrile phase follows the 
initial stage after the afebrile, relatively asymptomatic period or some patients note the 
improvement in their condition(20) but some papers reported mostly in Russian 
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language ( Kanter V., 1965; Leonova G., 1987) that tick-borne encephalitis caused by 
Far-Eastern Subtype doesn’t have the interruption as a relatively afebrile period and 
have only monophasic course of the disease(21). The second febrile phase is 
characterized by central and peripheral nervous system involvement. The damage of 
the central nervous system is characterized by meningitis, meningoencephalitis, and 
meningoencephalomielitis and with involvement of the peripheral nervous system. It 
was recognized that tick-borne encephalitis could be presented with various clinical 
signs of the nervous system damaging and it was differentiated into the various clinical 
forms as meningeal, meningoencephalitic, febrile, poliomyelitic, polyradiculoneurotic 
and chronic as welll(25)(26). 
Meningitis is the most frequent clinical form of tick-borne encephalitis (26). Meningitis 
is characterized by high fever, vomiting, vertigo, strong headache with photophobic 
suffering pain in the eyes, signs of meningeal irritation (26). Meningoencephalitis is also 
known as meningoencephalitic form of tick-borne encephalitis. Usually, it is combined 
into the meningoencephalitic form and polyomyelitic form into the 
meningoencephalomyelitic form(26). The meningoencephalomyelitic form of tick-borne 
encephalitis is presented by fever, not specific symptoms of common intoxication, signs 
of meningeal irritations and the signs of the brain substance damage that lead to the 
paralysis. (27). (27) (21) (28). The paralysis in meningoencephalomyelitis is often 
presented by flaccid poliomyelitis like paresis, and this type of paresis commonly affects 
the upper extremities as the shoulders, arms, muscles of the head elevators (27). In 
severe case the outcome of the disease form could be the death, the death could occur 
in 7 days after the onset of neurological signs and especially in a case of the bulbar 
involvement and diffuse brain edema. 30% of cases of this central nervous system 
sequelae are ended by death (90). (27) (25). In some proportion of patients occur as the 
abortive form of tick-borne encephalitis (91). This form is presented with clinics of febrile 
illness without the involvement of the central nervous system. The data over this form is 
limited, in Europe, only 2 % of patients develop this form (88), however, in Russia and 
Kazakhstan, this form is included in the commonly accepted classification and called 
“Febrile form of tick-borne encephalitis.” It was classified differently into the separated 
form as the incidence of this form is up to 50% (Ustinova et al., 1997) (91) (77). The 
special form of tick-borne encephalitis is a chronic form. The chronic form is 
characterized by progressive physical deterioration and frequently accompanied by the 
alteration of mental health. The decline of physical health includes the damages of the 
nervous system. The clinical manifestation of chronic tick-borne encephalitis is varied 
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and could be manifested by Kozhevnikov’s epilepsy, progressive neuritis of the shoulder 
plexus, lateral sclerosis, dispersed sclerosis, a Parkinson like a disease, progressive 
muscle atrophy(26). (Pogodina et. al 1986, Votyakov et al., 1976)(25)(26) . (29). (95). 
 Tick-borne encephalitis has a significant impact on public health (30) as the post-
encephalitis syndrome is developing after the acute tick-borne encephalitis. This 
syndrome is characterized by flaccid paresis, damages of cranial nerves as hearing 
loss, tinnitus and disturbance of vision. (31). (31). (32). (26) In average 10% of patients 
develop the permanent paresis, although in Russian publications the developing of 
permanent paresis in 25 % of patients was reported.  
Treatment of tick-borne encephalitis is complicated and depends on the severity of 
clinical manifestation. There does not exist the specific treatment of antiviral treatment. 
Patients require the detoxication therapy for water and electrolytic balance but with the 
strict diuresis control. Also, the supportive therapy requires administration of 
antipyretics, analgesics in a case of high temperature and pain. In a severe case with 
the cerebral nervous system involves the administration of anticonvulsive therapy is 
necessary. The critical patients due to the neuromuscular paralysis and involvement of 
the medulla oblongata have the respiratory failure. Therefore, these patients need 
intubation and assisted ventilation. One of the dangerous complications is brain edema. 
Brain edema is usually a bad prognostic sign and could be ended in death. The therapy 
against this complication typically prescribed a dehydration therapy and an 
administration of steroids (22) (22). Despite the absence of the specific treatment 
against tick-borne encephalitis recognized worldwide, in Russia and Kazakhstan the 
intramuscular Immunoglobulin is recommended in a case of tick-borne encephalitis (The 
recommendations of TBE treatment in Russia, 2013))(33). It is clear that the 
administration of Immunoglobulin against tick-borne encephalitis virus is dangerous as 
the Immunoglobulin could transmit HIV, the viruses of hepatitis B, C, D and could be a 
cause of severe allergic reactions. And the treatment with human immunoglobulin is no 
longer available in European countries but due to the circulation of Siberian strain and 
Far-eastern strain of tick-borne encephalitis that have a high tropism to nervous cells 
the intravenous and intramuscular human immunoglobulin against tick-borne 
encephalitis is recommended in high doses (Zaharcheva et al., 2013). In 2013 in Russia 
was conducted the study over the efficacy the Immunoglobulin. It was demonstrated 
that The Immunoglobulin efficacy correlates with the form of tick-borne encephalitis, the 
severity and the most important with the time of immunoglobulin administration. It was 
noted the rapid involution of neurological symptoms especially in patients with 
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encephalitis with focal symptoms. Also, the sanitation of cerebrospinal fluid was earlier; 
the post-encephalitic syndrome is shorter without severe impairment of the central 
nervous system was significant in comparison with the control group (p<0.05). 
(Zaharcheva et al., 2013). The new schemes of treatment with Immunoglobulin was 
suggested and later approved and accepted in the Russian Federation.(34).  
 The human intramuscular immunoglobulin is also available and recommended by 
the Kazakh Health Care system (Recommendation for Tick-borne encephalitis 
treatment, The protocol #9 from 16 August 2016) (34). 
The experimental study on a mouse model (Knockout CD8) demonstrated that the 
immune system plays a substantial role in TBE developing. (35). This experiment 
highlighted the importance of the immune system as one of a crucial mechanism of cell-
damaging and the new ways of the ideal treatment of tick-borne encephalitis. The ideal 
treatment should enhance the immune response against TBEV, but at the same time to 
suppress the damaging effect of the immune system. Also, one of such treatment is 
high doses of intravenous generic immunoglobulin against tick-borne encephalitis virus 
could be. (35). Despite the fact of limited validated data over the Immunoglobulin 
administration in some countries it is highly recommended. Hence, even though the 
studies demonstrate the efficacy of high doses of immunoglobulin the administration of 
human Immunoglobulin against tick-borne encephalitis is under the big debate and 
requires further validated studies on the efficacy and risks of it 
 
2.1.1.4  Vaccines against TBEV 
The vaccination is the most useful measurements again tick-borne encephalitis. The 
active immunization against tick-borne encephalitis virus decreased the incidence of 
tick-borne encephalitis in 1940 in the Far Eastern region of Russia and 70s in 
Austria(14)(26). Currently, four vaccines are available FSME-IMMUNE (Baxter/Pfizer, 
Austria), Encepur( Novartis, Germany), EnceVIR (Tomsk, Russia) and IPVE (Moscow, 
Russia) although the fifth vaccine was produced in China by Changchun Institute of 
Biological Products(36). Some countries with endemic regions for tick-borne 
encephalitis implemented the vaccination program regulated by Government. These 
countries are Russia, Austria, Finland, Hungary, Latvia, Slovenia, Switzerland, and Italy 
(30). In Kazakhstan only, the groups of risks in endemic regions are under the 
vaccination program (Recommendations on TBE, 2016, Health Care of Kazakhstan). 
Two vaccines FSME-IMMUNE (Baxter/Pfizer, Austria) and Encepur (Novartis, 
Germany) are based on European strains of TBEV, two vaccines EnceVir (Tomsk, 
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Russia) and IPVE (Moscow, Russia) are based on Far-Eastern strains of TBEV, and 
Chinese vaccine is also based on Far-Eastern strain of TBEV. In detail FSME-IMMUNE 
(Baxter/Pfizer, Austria) based on Neudorfl strain, this strain was isolated from the ticks 
Ixodus (I) ricinus collected in the surroundings of Vienna in 1971(37) Encepur (Novartis, 
Germany) based on Strain K23, this strain is also isolated from ticks i.ricinus in 1975. 
EnceVIR (Tomsk, Russia) is based on strain 205, this strain was isolated also from 
ticks, but from I.persulcatus in Khabarovsk region in 1975(36) while IPVE (Moscow, 
Russia) vaccine based on Sofjin strain isolated in 1937 in Far-Eastern region from the 
patient’s brain (36). Chinese vaccine is also based on a strain with high homology with 
Sofjin strain and isolated from the patient’s brain in 1953(38)(36). The data on the 
Chinese vaccine is limited. Moreover, this vaccine only was registered and administered 
in China.)  (33). (36). Moreover, the experimental studies on the efficacy of these 
vaccines against the all known strains found out that vaccines FSME-IMMUNE 
(Baxter/Pfizer, Austria), Encepur (Novartis, Germany), EnceVIR (Tomsk, Russia) and 
IPVE (Moscow, Russia) induces neutralizing antibodies in protective titers against all 
known strains. (39). Despite the all vaccines induce the cross-protective immunity for all 
known strains, the phylogenic diversity could slightly influence efficacy and the strain 
peculiarities as well. Recent experimental studies demonstrated that E protein could be 
used as the target part for a recombinant vaccine against TBE developing. There was a 
developed an experimental vaccine including the recombinant TBEV E protein domain 
III immobilized on a dextran. It was noted that sequences of domain III are conservative 
among all flaviviruses and the neutralizing antibodies were found against this domain in 
sera. Due to these properties, the E Protein was a proposing part of tick-borne 
encephalitis virus for a vaccine and new diagnostics kit developing. However the 
protective efficacy was not proved, but it is a basis for further vaccine approaches 
developing(40).  
 
2.1.1.5  Biosafety containment of TBEV 
All diagnostics methods except the work with a virus cultivation could be provided in 
laboratory Biosafety level 2, but the clinical samples should be inactivated by AVL 
(Qiagen, Germany) for molecular methods of diagnostics or by heating during 560 C 
during 30 min for further serological investigation to according to the 
recommendations(41)(42)(43)(44)  
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2.1.1.6  Diagnostics of TBE 
I described the methods as we developed SOPs on diagnostics during the project 
study and they were implemented in KSCQZD.   
Rapid and timely conducted of TBE diagnostics is important. Currently, the 
diagnostics based on molecular methods and serological methods investigation are 
available. 
According to recommendations of European center for disease control meeting report 
from 2011, TBE diagnosis demands both clinical symptoms and laboratory findings as 
the detection of viral RNA in clinical samples or IgM and IgG in serum, or IgM and IgG 
in cerebrospinal fluid (45). In a case of epidemiological surveillance of TBEV natural 
foci, ticks collected in fields or collected from the livestock, wild animals, rodents are 
investigated for the presence of TBEV RNA. In some cases, the organ homogenates of 
wild animals usually rodents are investigated for the presence of the viral RNA. In the 
endemic region for TBE, the blood of the livestock could be tested for the presence of 
antibodies against TBEV(46). 
Molecular methods of investigation 
Previously, the detection of viral TBEV RNA was detected in ticks and clinical 
specimens separately. For detection, the viral TBEV RNA in ticks the nested RT- PCR 
(120) (121) (122) and the RT-PCR based on TaqMan chemistry (123) were used. At the 
same time, the applying RT-PCRs assays in detection of viral RNA in clinical specimens 
were also developed and performed as the nested RT-PCR assays (124) (125).  
Currently, protocols updated for different commercial chemistries and targeted to 
detect E gene of TBE viral RNA are available. (126).(127). The modern molecular 
methods of TBEV investigations must be targeted to the rapid and accurate detection of 
the viral RNA in a material as in clinical specimens and ticks for epidemiological 
observations as well. In 2013 was presented a novel RT-PCR assay based on TaqMan 
chemistry (47), the assay was developed to detect all known subtypes of TBEV as the 
maximum homology within 3'non- coding region of four strains Neudoerfl, Vasilchenko, 
strain 263, and strain Hypr (119). This RT-PCR was used in our research project 
Serological methods of investigation.  
The diagnostics of tick-borne encephalitis in clinics are mostly based on serological 
methods. The applying of this approach in clinics are explained by the developing of the 
disease and changing the phase of viremia (first 1-6 days) by the following phase of 
immune response and antibodies releasing (48). Patients usually are admitted to the 
hospital during the second phase of the disease, when the neurological symptoms 
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occur and to find the RNA of TBEV is rarely successful. Also, it is more likely that 
antibodies IgM against TBEV would be detected approximately on and after the sixth 
day after the onset in serum and after six weeks the activity of IgM is declined. IgG 
antibodies appeared in serum later and could be revealed up to one year. In 
cerebrospinal fluid, IgM antibodies could be detected from the 9th day after the disease 
onset(45). Therefore, in hospitals, the serological methods of investigation of TBEV are 
prevailed (48). Currently, various diagnostics tests form the serological methods of 
investigation. One of the widely used is the enzyme-linked immunosorbent assay 
(ELISA). Currently, there are many available commercial kits on detection of IgM and 
IgG antibodies (49)(50).  
 
2.1.1.7  Epidemiology and vectors of TBE 
 Tick-borne encephalitis is a significant health care problem. Annually up to 15000 
cases are registered annually (51). People are infected through the tick bites or 
consumption of raw infected milk. The domestic animals are the host for ticks spp. 
Ixodes. Hence, ticks infect animals. Despite the livestock do not show any clinical signs 
and do not develop the disease, infected animals play a substantial epidemiological role 
as they are a source for the so-called alimentary acquired TBE (52). 
 The main reservoir for the virus circulation in nature are small mammal species as 
they can transmit the virus through the viremia and can infect other ticks through the co-
feeding and feeding. It was observed that certain rodents are an important reservoir for 
TBEV. Moreover, the reservoirs are distinguished by circulating virus subtype. For 
example, in Europe with European subtype, the rodents Apodemus (A.) flavicollis, A. 
sylvaticus , and Myodes spp. are the main virus reservoir (13) whereas in Siberia with 
Siberian subtype are A. peninsula and A. agrarius and in Far-Eastern region with Far-
Eastern subtype Myodes rufocanus and Microtus arvalis respectively. After discovering 
the new two subtypes Baikalian and Tibetian (18), the main reservoir of these subtypes 
is still unclear. However, the number of mammalian species that could be a host for 
ticks are significant. 
The tick parasites the host animal according to its stage development. Larvae and 
nymphs are preferring to parasite and feed on small forest animals, mainly on mouse 
rodents or on medium sized animals. However, the range of animal's size could be 
varied to large hosts. Imago parasites mostly on medium size and large hosts (53). 
Ticks could be infected not only through feeding and co-feeding but also through a 
transovarial transmission. In the territories of western Europe countries, Turkey and the 
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territories expanding to the southeast to Caucasus and Iran the main vector of TBEV is 
ticks I. ricinus , whereas in the territories of eastern Europe countries, Japon, China, 
Mongolia (54) and Kazakhstan the main vector of TBEV is tick I. persulcatus. I. 
persulcatus and I. Ricinus could co-circulate on territories of Russia, in some countries 
of Eastern Europe, Estonia and Latvia (27)(55). In Siberia and far-Eastern region, the 
third species similar by ecological features is I. pavlovsky. Currently ticks I. pavlovsky 
and hybrids I. pavlovsky with I. persulcatus are becoming the main vector in Siberian 
surroundings (56) However other tick species could be a vector of tick-borne 
encephalitis. Recently, it was observed that in some natural foci of TBEV in Russia the 
main vector of TBEV tick spp. Dermacentor. The circulation of the virus is supported by 
tick spp. Dermacentor. For example, the main vector of TBEV in the Republic Altai of 
Russia is tick spp. Dermacentor. Due to the absence of tick I.persulcatus in these 
territories the main vector of tick-borne encephalitis is Dermacentor nuttalli. However, 
this tick species is more prominent and therefore not so mobile as ticks I.persulacatus, 
and usually, people could remove them before a bite (Shuchinova et al., 2013) (46).  
The epidemic potential of natural foci of TBEV is varied and depends on many 
factors as landscapes, peculiarities of circulating virus (mostly subtype), the density of 
vectors and their infection rate. One of the critical factors is the weather conditions and 
climate, as the weather condition influence the density of hosts. Moreover, it was 
observed that I. ricinus and I. persulcatus depends on the humidity level. Thus, I. ricinus 
and I .persulcatus successfully adapted to different types of forests in the temperate 
zone of Eurasia. These species have high ecological plasticity, which is manifested in 
their ability to successful existence in several types of forest formations from the 
extreme north of the taiga zone and deciduous forests in the southern parts but with 
optimum humidity. I. ricinus is common in territories from England and Ireland in the 
west to the Volga - in the east. This species reaches the highest abundance in the zone 
of deciduous forests, but also could inhibit the territories in the north with mixed and 
coniferous forests of Scandinavia and Karelia and in the middle-taiga forests of Russia 
(Filippova, 1977). In the humid and maritime climate of countries of Western Europe, I. 
ricinus could inhabit not only in forests but also in open pasture type biotopes with 
coarse cereal grasses, moorlands, and bushes. In countries of the Mediterranean belt, I. 
ricinus inhabit the moisture-proof and cool forests in river valleys and on the northern 
slopes of the mountains (Gilot e. a., 1975; Kalteririeder E. a., 1985). The territories of 
the middle-taiga, southern taiga and broad-leaved forests from the Baltic to the Pacific 
Ocean, including Manchuria and Japan are inhabited by ticks I. persulcatus. Also, 
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I.persulcatus inhabit the territories of medium and south taiga forests and deciduous-
coniferous forests of the south of the Far East, but within these territories, I. persulcatus 
ticks are absent as in marshy areas and on the highly sparse pine forests on sandy soils 
areas as well. The distribution of I. persulcatus ticks to the north is limited by the sum of 
the temperature of at least 1400-1600 ° during the warm season. In the north parts, they 
could inhabit only the areas provided with optimal temperature. Thus, in the North i. 
persulcatus ticks do not expand 63 °northern latitude, and in the European part of 
Russia, the distribution of I.persulcatus is limited by to 64 ° northern latitude. The 
distribution of ticks I. persulcatus to the South is limited by humidity deficit, where 
this species is inhabited in isolated forests, in forest-steppe, Siberia and the coniferous 
forests of Tien Shan (Korenberg, 1979). The ticks I. ricinus and I. persulcatus have 
limited mobility. The maximum distance for larvae of I. persulcatus from the hatching 
site is up to 1.5 m (Levin, 1987). The imago of I. persulcatus could only crawl 5-5.7 m, 
usually, this distance does not exceed five meters toward the direction of the victim 
smell (Balashov, 1958; Arumova, 1979). The tick distribution mostly is carried out by 
animals and birds. In a case of larvae and nymphs of I. persulcatus, the distance is 
limited by tens of meters as they parasites mostly on small rodents. Small distances 
limit the migration of small rodents. However, in a case of parasitizing on rabbits or 
hedgehogs or other medium-sized animals the distance of tick's migration could achieve 
a hundred meters. Large animals as moose and birds could transmit the ticks for long 
distance. Birds are an ecological niche for diseases transmission for a long distance. In 
literature, it was mentioned that infected I. ricinus was taken off from a bird and the 
transportation of the viruses into the new not endemic areas is a common event(57).  
Moreover, in old literature was noted that the birds play a huge role in a tick 
transmission. In Ukraine for a time period of less than 80 years has populated and 
reached a high number of I. ricinus of the artificial forest plantations “Askania-Nova”, 
surrounded by large ploughed fields (Emchuk, 1972). Larvae and nymphs of I. ricinus 
was constantly taken off from migratory starlings, thrushes and other species of 
migratory birds in the Baltic region (Brinck e. a., 1965). 
Usually larvae and nymphs feed on an animal 2-6 days and female imago - 6-12 
days. The feeding or parasitic time does not exceed o1.4-2% of the total duration of 
their life cycles. Each of these short feeding periods is divided by many months of life 
and development of I. persulcatus in the forest floor and grass layer. So, I. persulcatus 
ticks during this time behave like typical tillage or plant-dwelling organisms. They 
constantly lose water for transpiration through the integuments of the body and face the 
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danger of drying, and a danger of the death from low temperatures (Balashov, 1989). 
The optimal humidity of environment is an important factor for surviving the ticks of I. 
ricinus and I. persulcatus as well. In the environment lack of humidity, hungry ticks I. 
persulcatus and I. ricinus usually face with the death (Balashov, 1989). The fed I. 
persulcatus ticks could face the mortality when after the feeding on an animal ticks I. 
persulcatus falls off into habitats not suitable for their further development as treeless 
meadows and pastures, marshes, etc. However in a case ticks I. persulcatus falls off in 
favorable conditions for them as litter, sod of plants and soil microwaves, the risk of 
death from drying out or overheating is minimized. Due to the development of the 
complex of adaptations for seasonal climatic conditions the ticks I.ricinus and I. 
persulcatus could survive during the severe winter. And one of such survival 
mechanisms is a diapause. The fed female imago could not have a diapause. But there 
are also the difference in ticks, I. ricinus ticks have the diapause in all stages of 
development while I. persulcatus could have the diapause only the larvae and nymphs 
and starving female imago. If the weather conditions are favorable the ticks of all stages 
and different time period and years of feeding are activated. In a case of not favorable 
weather condition a significant part of ticks can continue diapause. And after the 
surviving through the not favorable the activated ticks consist of different stage from 
larvae till imago and different year of hatching. Thus, for natural foci of tick-borne 
infections are characterized by extremely complex system of biocenotic bonds. In fact, 
the natural focus of infection includes several interrelated or partially independent 
parasitic systems, each of which supports its own natural path of pathogen circulation. 
Ticks as biological carriers of these pathogens have not only a transmissible role by 
receiving and transmitting pathogens but could save and transmit the pathogens without 
the participation of vertebrates within their populations by transovarial and sexual ways.  
 
2.1.1.8  Tick-borne encephalitis in Kazakhstan  
 The symptoms of TBE or also called Russian spring-summer encephalitis (RSSE) 
was described in patients from Almaty and Almaty oblast in 1935 by Steblov (58). TBEV 
was isolated in Kazakhstan for the first time in 1941 by Chumakov. For this isolation, he 
used the brain from a patient who died on TBE from Almaty oblast (11). In 1947, 
Linetskaya isolated TBEV for the first time from the tick species I. persulcatus using 
suckling mice which were suggested by Chumakov (59) (23). However, only in 2014, 
the first molecular biological data from a TBEV strain (Almaarasan) which was collected 
in 1977 in Almaty Oblast was published in by Lvov (60).  
18 
 
Kazakhstan shares the borders with countries which are endemic for Tick-borne 
encephalitis virus, e.g., in Russia (18) (19), China (17)(25)(26), Kirgiz republic (27) and 
Mongolia (28) (29). Further, Kazakhstan has a wide range of climatic and vegetation 
zones with favorable conditions for different vectors of zoonotic diseases like TBEV 
(22)(30). Characteristical TBEV endemic zones in Kazakhstan seem to be mountains 
(61) and forest-steppe zone like the landscape of Almaty, Almaty Oblast and in East 
Kazakhstan Oblast. In the South of Kazakhstan, the natural foci of TBEV are mountains 
Tyan-Shan and foothills of mountains Tyan-Shan. These foci do not have any 
connection with the West-Siberian group of TBEV foci. In the East of Kazakhstan, the 
natural foci of TBEV are in forest and forest-steppe zones. These foci located not far 
from the Tobol-Ishim foci of the West-Siberian group of TBEV foci. Moreover, these foci 
are adjusted to the Altai foci of TBEV (8). 
 According to landscape, there are four natural foci of TBEV as the South 
Kazakhstan foci, forest-steppe and steppe foci, the steppe focus, semi-desert focus (8).  
 The TBEV South Kazakhstan focus: this focus includes the mountain Tyan-Shan, 
foothills of mountains Tyan-shan and the South Altay mountains. It characterized as 
forest-steppe zones at altitude 1500-1700m and meadow and steppe zones till 2700m. 
The meadow and steppe zones are divided into the low belt with the aspen forest (up to 
2100 m), the middle belt with the spruce forest (up to 2300m.) and the high belt with the 
spruce forest, meadows and steppe. In average, the temperature in summer is +23, and 
in winter is- 7.40C. The annual precipitation is 560 mm. The main vectors of TBEV are 
I.persulcatus, although ticks I.pavlovsky also inhabit this focus. Moreover, tick 
D.marginatus, D.pictus, and H.punctata are collected in this area. This focus includes 
Almaty oblast (area) and the East Kazakhstan oblast (area). These oblasts (areas) are 
recognized as endemic oblasts for TBE (61) (8). 
Forest-steppe and steppe focus of TBEV. This focus is in the center of Kazakhstan 
and includes two oblasts (areas) Kostanay and Akmola oblasts (areas). The virus was 
isolated from a patient with TBE and ticks spp. Dermacentor in 70th. Till 2017 this focus 
was inactive, but since 2017 the cases of TBEV have been registering by authorities. 
Also, the investigation of this focus is necessary. Mainly two types of ticks prevail D. 
marginatus and D. pictus in this focus.   
The steppe focus. This focus is also located in central Kazakhstan and located in 
Karaganda oblast. This focus was also recognized in the middle of 70th a focus of 
TBEV. The virus was isolated from a patient and ticks spp. Dermacentor. Currently, this 
focus is inactive. However, some TBEV cases started to register since 2017. 
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Semi-desert focus. This focus was found occasionally during the research. It is not 
typical for TBEV landscape because the sand desert Saryesik Atyrau occupies the 
landscape of this focus. The investigation of ticks from this focus revealed positive ticks 
D. niveus, Hyaloma asiaticum. This focus is not active. The foci with forest landscapes 
have the highest activity whereas the foci with the steppe and desert landscapes have 
the lowest activity, mostly is not active(62). Despite the ticks, I. persulcatus is the main 
vector of TBEV in Kazakhstan, it was revealed that ticks of the other 12 species were 
positive for TBEV. These ticks species are I. pavlovskyi, I. trianguliceps, I. gexagonus, I.  
gibbosus, Haemophisalis concina, H. japonica, H. inermis, Dermacentor marginatus, D. 
silvarum, D. reticulatus, D.nuttali (63). However, this data should be rechecked as in 
70th and 80th the diagnostics approaches were different and mainly  methods based on 
antigen detection  were used as direct hemagglutination reaction and 
immunofluorescence test (63) (63). TBEV could have a cross-reaction within the 
flaviviruses (64).  Moreover, according to the recent study, the circulation of other 
flaviviruses as West Nile virus could be on the territory of Kazakhstan and adjusted 
territories (6).  
Therefore, the investigation of this foci is under a big necessity.  
During the observation was noted that the large ungulate animals are the host as for 
imago I.persulcatus and larvae and nymphs of I.persulcatus as well(61).  
 In Kazakhstan two oblasts (areas) are endemic for TBE as Almaty and the East 
Kazakhstan oblasts (areas) as well (figure 2).  
 
 
Figure 2. The endemic oblasts (areas) for Tick-Borne encephalitis in Kazakhstan 
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TBE cases in Kazakhstan are on a constant high level with reported incidence rate to 
be 0.16/100.000 up to 0.32/100.000. Approximately 50 cases are registered annually. 
Refer to the annual report of the Scientific Practical Center of Sanitary Epidemiological 
Expertise and Monitoring during the last three years (2016-2018) 126 cases of tick-
borne encephalitis were registered. Moreover, according to this report since 2018 TBE 
cases have been started to register in the North and the center of Kazakhstan.  
Despite this increased awareness, there is still a lack of data regarding the circulating 
TBEV strains and their molecular biological data. The data over the TBE cases mainly 
formed from the medical facilities reports based on clinical and epidemiological 
peculiarities. Despite the annual reports on tick bites and reported TBE incidence there 
is only a few compressed data are available on the infection rate of TBEV in ticks in 
endemic areas, so far. 
Moreover, since 2017 in TBEV foci, previously inactive, the TBE cases have been 
started to register. Most of the cases could remain truly undiagnosed as only serological 
methods of investigation are available in laboratories and serological approaches based 
on commercial kits with unknown specificity. Moreover, it is a big debate whether it is 
true TBEV in again active TBEV foci or another flavivirus. The data over the actual 
condition of natural foci of TBEV needs to be updated. The aim of this thesis to discover 
some posed questions and make the basis for future studies in this field. However, the 
most substantial part of this project that it will bring knowledge over TBEV and improve 
as surveillance system over TBEV and also diagnostic approaches of this infection in 
medical facilities. 
 
2.1.2  Literature review. Congo-Crimean Hemorrhagic Fever (CCHF)  
 Crimean-Congo Hemorrhagic Fever is an infection caused by an arthropod-borne 
virus, the Crimean-Congo Hemorrhagic Fever. This arboviral infection has a specific 
clinical manifestation such as hemorrhagic fever with a high fatality rate up to 30%(65).  
 
2.1.2.1 History of CCHF  
CCHF has been known for centuries. The first mention about the disease was 
published as early as the XII century (1100) in Persia in work "The Treasure of 
Khorezmshah” by the Dzhurzhani. He described a disease that was close or identical to 
CCHF and had a clinical manifestation with abundant nasal, gastrointestinal, pulmonary 
bleeding and gingival bleeding as well. The disease was associated with a tick bite 
parasitic on a black Griffin. The existence of CCHF in Central Asia in remote times was 
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pointed out by many modern authors. For centuries, this disease has been known in 
Tajikistan and Uzbekistan under the various names. Historically the name of the 
disease is originating from cases occurring in summer 1942 in hospitals of the occupied 
Crimea. 18 cases of peculiar gastric bleeding observed in Stalinbad (currently 
Dushanbe) were described in 1944. The respective disease was called acute infectious 
capillary toxicosis, by its clinical and epidemiological characteristics, and so fully 
matched the clinical symptoms of CCHF. Afterward, in 1944-1945 an outbreak of severe 
febrile illness with severe hemorrhagic syndrome occurred in the Crimea within 
approximately 200 soldiers. The disease was characterized by a lesion of the vascular 
system and was initially designated as “acute infectious capillary toxicosis” and 
thereafter named by. Chumakov as “Crimean hemorrhagic fever” (66) 
Many species of a laboratory, domestic, and wild animals (including adult white mice, 
guinea pigs, monkeys, and cats) were resistant to infection with virus-containing 
materials. However, in 1945 Chumakov et al. established the viral etiology of CCHF by 
the reproduction of this disease in psychiatric patients who needed pyrogenic therapy. 
Later, it has been shown that the suspensions of Hyalomma plumbeum ticks and the 
blood of patients with CCHF contained a viral pathogen detecting even after passing 
through small-pore filters and caused the disease with a clinical manifestetion of CCHF. 
In 1967, it was decided to use the method of intracerebral infection of newborn white 
mice - a model that at that time was extremely effectively used in foreign laboratories to 
isolate many arboviruses. Nine strains of CCHF virus were identified: a strain “Drozdov" 
from a patient of Astrakhan Oblast, seven from patients from Rostov oblast and one 
from a patient from Samarkand oblast (currently Uzbekistan). The evidence of the 
etiology of CCHF was completed by the consistent detection of seroconversion of 
specific antibodies in patients with a typical picture of the disease and the regular 
release of this virus from their blood during the acute phase of the disease. Serological 
discrimination to 20 other arboviruses was shown in 1968 the CCHFV strain "Drozdov" 
was transferred to the arbovirus laboratory (YARU) at Yale University, USA, to identify 
the similarity between the strain Drozdov (a prototype of Crimean Hemorrhagic Fever 
Virus) and strain Congo. This strain was isolated S. Courtois in 1969, in the medical 
laboratory of Stanleyville (Zaire, Belgian Congo) from the blood of a sick child(67).  
Taxonomic status was established in 1969 when the V3011 strain of the Congo virus 
was found in Uganda. As a compromise between the "unofficial" historical priority and 
the "official" registration criterion, Casals and co-authors (1970), suggested the general 
name of the Crimean-Congo Hemorrhagic Fever Virus, which was adopted in the 
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international scientific community. The substantiation of the etiological unity of this 
infection in the endemic regions of Europe, Asia, and Africa. Moreover, the most 
valuable is the determination of the biological and morphological characteristics of the 
virus. Hence this finding allowed establishing its belonging to the family Bunyaviridae.  
 
2.1.2.2  Microbiology of CCHF  
Recently the taxonomy of CCHFV was changed. Crimean Congo Hemorrhagic Fever 
virus now belongs to the genus Orthonairovirus, family Nairoviridae, order Bunyavirales 
(ICTV taxonomy.2017 [released 12 March 2018]) https://talk.ictvonline.org/taxonomy). 
The genome of CCHFV contains three segments RNA with the large (L), the Medium 
(M) segment (~5.5 kb) and Small (S) segment (~1.6 kb). The L segment (12.5 kb) 
encodes a Large (L) protein and contains the multiple and highly conserved domains as 
the RNA-depended RNA polymerase, an Ovarian Tumor (OUT)-like cysteine protease 
domain and a zinc-finger domain (68). The size of L protein in comparison to other 
segmented negative-stranded viruses is ~450 kDa twice prominent. Also, this protein 
plays a significant role in virus transcription and counteracts the possible immune 
response of a host (69) as on the N terminus of L protein located the ovarian tumor 
domain. This domain is responsible for suppressing the immune system of a host cell 
(70). The medium (M) segment encodes a unique polyprotein. It is processed into the 
polyprotein in the endoplasmic reticulum. Later, this polyprotein is cleaved into pre-GN 
and pre Gc precursors. These pre-Gn and Pre Gc precursors require the activity of 
cellular serine and endo-proteases as SKI1 or SIP and furin for maturing into Gn and Gc 
proteins. These proteins are crucial for immunity and pathogenicity.(71). CCHFV could 
interact with host cell surface receptors only via GN and GC glycoproteins. Moreover, 
the GN and GC glycoproteins are the primary target for neutralizing antibodies. This 
ability could be used in a vaccine creating, and treatment as some studies reported that 
convalescent human sera could release the protective mechanism in an acute phase of 
the disease (72) (73)(74). The small (S) segment encodes the nucleocapsid protein that 
is responsible for encapsulation (75). Phylogenetic analyses of CCHFV by comparing S 
segments shows seven geographically separate genetic clades due to the IV clade is 
divided into two different clades Asia 1 and Asia 2(76). Whereas by M segment this 
clustering is into six clades (77).  
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Table 1. The phylogeny grouping of CCHFV by S segments 
 Clades   CCHFv groups  
Clade 1  1. .West –Africa  
Clade 2 2.  Central Africa  
Clade 3 3. South Africa and West-Africa  
Clade 4  Middle 
East and 
Asia  
4. Asia 1 
5. Asia 2 
Clade 5 6. Europe Clade  
Clade 6  7. Greece  
 
However, according to Hewson et al., 2004 the phylogeny grouping by M segment is 
different. Also, it was established that segmented RNAs is more vulnerable to 
reassortment if (78). This evidence was also observed during the project study. 
 
2.1.2.3  Clinical presence of CCHF  
It is still not clear whereas the geographical distribution could affect the virulence in 
human (79), but some studies show that strain AP92 from Greece had asymptomatic 
and mild clinical manifestation (80). Usually, the clinical manifestation is developing in 
four stages: The incubation, the pre-hemorrhagic phase, the hemorrhagic phase, and 
the convalescence(81). The severe cases could progress into a clinical presence with 
disseminated intravascular coagulation(DIC), shock and heavy bleeding (75). The 
reasons for the severity of CCHF clinical presence is still under the question. Moreover, 
according to some studies the late or the absence of antibody response (82) (83) is a 
predictor of fatality or severe clinical presence of CCHF. The fatality rate reaches 
30%(65). However, many studies show that clinical presence of CCHF could be 
presented only with not specific symptoms as fever in a certain proportion of patients in 
endemic CCHF region and it is usually remained undiagnosed by physicians (5)(2)(84). 
 Despite the absence of the generally accepted classification on the clinical 
manifestation of Crimean-Congo Hemorrhagic Fever, most authors use the generally 
accepted scheme of distinguishing the clinical presence into severe, moderate and mild 
forms (Clinical recommendation for CCHF, 2014, Russian Federation) (85). The 
description of Crimean-Congo Hemorrhagic Fever by their severity (66)  
A mild form of Crimean-Congo Hemorrhagic Fever is observed in 9.5% of cases. This 
form of the disease is characterized by short-term sub febrile fever. The symptoms of 
intoxication are mild and are manifested by drowsiness, lack of appetite, general 
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malaise and moderate bradycardia as well. The hemorrhagic syndrome is manifested 
by an abnormal, rapidly disappearing rush. The nose bleeding is observed rarely, and 
usually, the nosebleed is not abundant. The Blood picture is characterized by moderate 
thrombocytopenia, leucocytes level is within the normal range, but in some cases a 
slight leukopenia. The outcome of the disease is favorable.  
The moderate form of Crimean Congo Hemorrhagic Fever was observed in 26.2% of 
cases. Fever is lasted 4-5 days approximately and reached high numbers. Symptoms of 
intoxication are expressed: weakness, exhaustion, drowsiness, blood pressure 
decreasing, weakness and bradycardia as well. However, some patients suffer from 
tachycardia. A hemorrhagic syndrome is manifested by gingival bleeding, profuse 
hemorrhagic eruption. The rush is increasing. Also, the hemorrhages are presented at 
injection sites. Bleeding is abundant and often repeated as well. In the blood picture, 
such changes could be observed: leukopenia, anemia, thrombocytopenia. The outcome 
of the disease usually is favorable. 
The severe form of Crimean-Congo Hemorrhagic Fever was observed in 64.3% of all 
cases. The disease is characterized by acute development. The initial period is shorter, 
not more two days and lasting on average 1-2 days. Approximately temperature is 
reached 39–40 ° C. The symptoms of intoxication are severe and includes nervous 
system lesions. Several patients have delirium, hallucinations, loss of consciousness. 
Also, meningism and focal neurological signs could be observed. Most patients have 
tachycardia, hypotension, muffled heart tones, and in some cases, an arrhythmia is 
observed as well. A severe course of the Crimean-Congo hemorrhagic fever is 
characterized by abundant, repeated bleeding (nasal, gastrointestinal, pulmonary, 
uterine), simultaneously from several organs. Blood loss could reach one-two litters. In 
the blood picture the number of erythrocytes decreased (2.0 * 1012 / l), leukopenia (2.0 
* 109 / l and below), thrombocytopenia reached 60.0 * 109 / l, and in some cases the 
number platelet count decreased to 7.0 * 109 / l - 4.0 * 109 / l. Complications are often 
developed in a severe form of Crimean Congo Hemorrhagic Fever. 50% of all severe 
cases of Crimean-Congo Hemorrhagic Fever was fatal. Recovery usually is slow. 
Despite such dividing of Crimean-Congo Hemorrhagic Fever into mild, moderate and 
severe forms In Kazakhstan the updated CCHF classification of Leshinskaya 1967(85)  
is used. This is also recommended by the Health Care Ministry of Kazakhstan. 
According to the classification (Leshinskaya, 1967), Crimean-Congo hemorrhagic fever 
is divided into Crimean-Congo hemorrhagic fever with the hemorrhagic syndrome and 
Crimea-Congo hemorrhagic fever without the hemorrhagic syndrome.  
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Classification of CCHF by Leshinskaya,1967.  
I. CCHF with hemorrhagic syndrome: 
1. A severe form of Crimean-Congo hemorrhagic fever: 
a) Without large hematomas on the skin and mucosal membranes and bleeding in 
cavities (epistaxis, hematemesis, melena, and intra-abdominal bleeding) 
b) With large hematomas on the skin and mucosal membranes and bleeding in 
cavities (epistaxis, hematemesis, melena, and intra-abdominal bleeding 
2. Moderate form: 
a) Without hematomas on the skin and mucosal membranes and bleeding in cavities 
(epistaxis, hematemesis, melena, and intra-abdominal bleeding 
b) With hematomas on the skin and mucosal membranes and bleeding in cavities 
(epistaxis, hematemesis, melena, and intra-abdominal bleeding 
3. Mild form. 
II. CCHF without hemorrhagic syndrome: 
1. The moderate form; 
2. Mild form. 
The severity of CCHF was determined by the following criteria: The intensity of 
intoxication, the level of hemorrhages, and a blood picture. Currently it was proved that 
the severity of CCHF and outcome as fatality correlates with the level of liver enzymes 
as alanine aminotransferase (ALT) ≥150 U/I, aspartate aminotransferase≥200 U/I and 
activated partial thromboplastin time (aPTT) ≥ 60 sec, fibrinogen ≤110 mg/dL(85)(86), 
counts of platelets (PLT)≤20×109/I, leucocyte counts ≥10×109/I(85)(86), counts of 
platelets (PLT)≤20×109/I, leucocyte counts ≥10×109/I (85)(86).  
Treatment of Crimean-Congo hemorrhagic fever  
The treatment of CCHF based on antiviral and supportive therapy. Currently, among 
the plurality of antiviral medicines, only Ribavirin is approved by WHO. The efficacy of 
ribavirin against CCHFV is still unclear, but some authors explain it is by its 
immunomodulatory effect (79) www.WHO.org, www.cdc.gov .  
  Some observational studies show the efficacy of Ribavirin, even most of the studies 
based on oral ribavirin even WHO recommends the intravenous form of ribavirin (87). 
However, the question of Ribavirin efficacy as oral and intravenous forms as well is still 
under big debates (88) as the only observational study was conducted and any 
randomized trials were conducted. Therefore, such observations could be biased (89). 
Many authors suggest including Interferon for the treatment of CCHF. The viral nature 
of the disease, pathogenetic validity and the proven efficacy of the use of Interferon type 
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1 in many viral infections provide the basis for the inclusion of Interferon in the 
combined therapy of CCHF. Interferon type 1 has anti-viral, immunomodulatory and 
anti-proliferative properties. It is now established that the protective antiviral effect is 
realized mainly through the activation of the immune system(66) and some authors 
mention its beneficial effect against CCHFV. The conducted experiment demonstrated 
that Interferon alfa and beta induces the releasing the MX (MX1 in mice and MXA in 
humans) proteins as well. During the same experiment, it was proved that MXA proteins 
have antiviral activity against CCHFV(90). (91). Later was proved that interferon alfa 
induces the expression of interferon genes. This expression could be necessary as a 
protective factor against CCHFV infection. CCHFV infected the pools of STAT1 Ko and 
WT mice. It was demonstrated that the lack of interferon genes expression was led to 
more rapidly the virus dissemination and fatal outcome.(92).  
The efficacy of interferon treatment is still taking the attention of scientist 
In some countries, also in Kazakhstan, the CCHF convalescent sera transfusions is 
widely applied in endemic regions for CCHF treatment. This method was suggested as 
early as in 1945. Despite positive outcomes there is still big question upon the efficacy 
of this method as not enough data is performed (88). However, in Bulgaria is a 
commercial specific human immunoglobulin "CCHF-venin" available (74). The 
supportive therapy as an infusion of blood components, transfusion of frozen blood 
plasma, infusion of fluids, respiratory support required as needed and should be 
considered in every case (93).  
 
2.1.2.4 Vaccines CCHF  
Due to the unavailability of effective vaccination, specific treatment and high mortality 
rate. Crimean-Congo hemorrhagic fever virus is included in biosafety level hazard risk. 
Moreover, the climate change and expanding the territories affected by the main vector 
of Crimean-Congo hemorrhagic fever virus ticks Hyaloma marginatum marginatum, 
globalization and international tourism to countries endemic for Crimean-Congo 
Hemorrhagic Fever as well(94). There is a high demand for an effective vaccine. 
Currently, only one vaccine against CCHF is known; this vaccine was produced and 
only licensed in Bulgaria. This vaccine was manufactured by using the Crimean-Congo 
hemorrhagic fever virus strain V42/81, an isolate from a patient suffered from CCHF in 
1981 and inactivated by chloroform, heating at 580C and adsorbed on Al(OH)3 
(Vasilchenko S., 1976) (95) (96). However, this only existing vaccine against the 
Crimean-Congo hemorrhagic fever; the efficacy of it is under the big debates as the 
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efficacy data is still unavailable (94). So, the new vaccine platforms are needed. 
Recently several studies on developing vaccines against the Crimean-Congo 
Hemorrhagic fever have shown their confidence in pre-clinical trials 
(www.cchfvaccine.eu). The different approaches were reported as DNA vaccine with an 
expression of determined CCHFV genes or the vaccines with viral or plant vector.(97) 
(98) (99) (100) (101) (94) (102).  
 
2.1.2.5  Biosafety containment of CCHF  
Biosafety containment of CCHF Due to high infectivity and unavailability of a 
protective vaccine, the absence of effective treatment CCHF is included in a group 4 of 
hazard risk and requires Biosafety Level 3- 4 laboratories to handle with positive 
CCFHV material or material suspicious for CCHFV according to international 
guidelines(103)(44) . Observational studies demonstrated the incidents of CCHFV 
laboratory-acquired infections and have a high risk for nosocomial infection (104) (43). 
Moreover, according to these recommendations before the manipulation with CCHF 
viral RNA, the samples contained the infected material should be inactivated (43). For 
serological methods the heating for 30 min at 560C. In experiments conducted in Africa 
for clarifying and analyzing the appropriate temperature for virus inactivation was 
proved that heating at 560 C inactivate sample (43)(105) In a case of molecular 
methods of investigation in an experimental study, the high efficacy of virus inactivation 
demonstrates AVL buffer contains a chaotropic salt ( Qiagen, Hilden, Germany)(106) 
(107) and TRIsolR LS reagent is a monophasic solution of phenol and guanidinidine 
isothiocyanate (Invitrogen corp.). Qiagen kits for virus RNA extraction includes this 
buffer, and this buffer does not inhibit the PCR (Qiagen mini-viral kit instructions). The 
ability of virus inactivation was proved by the absence of virus growth and plaques 
formation. These reagents are highly effective to inactivate the viruses of different four 
genera as bunyaviruses, flaviviruses, filoviruses, and alphaviruses (41). 
 
2.1.2.6  Diagnostics of CCHF  
 Timely started diagnostics and treatment are essential for good patient management 
and improving the ability of preventive measurements. Recent years several methods of 
diagnostics are developed and established. It could be divided into two big groups as 
molecular biological methods and serological methods of investigation as well. 
Molecular methods of investigation. 
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 The modern methods of molecular investigation is aimed for the rapid identification 
CCHFV in a field material as ticks and clinical specimens (108). 
However, the crucial point for the investigation of clinical specimens by molecular 
methods of investigation requires the exact time of blood withdraw approximately the 
within first five-six days after the disease onset. 
In 2005 for the first time was presented the method of one step real-time PCR assays 
for identification and quantification of viral RNA in a short time that is necessary for 
diagnostics of rapid developing CCHFV infection (109). So far, currently existing primers 
are designed for all lineages of CCHFV, as the highly conserved region of S segment 
was the target for this purpose. The viral RNA of 16 unique strains of viruses cover five 
lineages of CCHFV; these viruses previously propagated in vitro in a high biosafety 
containment. Remain two strains were synthesized according to the sequences in 
GenBank. These strains are AP92 from the lineage Europe2 (access number DQ 
211638 and DAK8194) and a strain from the lineage Africa 1(access number is 
U88411)(106). 
However, the assays are suitable only for those sequences available in GenBank. 
Moreover, it is crucial to design primers as new data on sequences are available in 
GenBank(6). “novel rapid RT-qPCR for detection of the various genotypes of 
CCHF”(110), or “Syber Green based one-step rRT-PCR”(111),  
As CCHF is mostly widespread in low- and middle-income countries, more rapid, 
cheaper assays and assays not demanding upon expensive machines were 
successfully developed in the recent years such as low density, field-applicable 
microarray CCHFV(112) , (113). Another functional assay in the field in remote rural 
areas are Loop-mediated isothermal amplification and colorimetric nucleic acid assays 
for CCFHV detection developed (114) (114) (115).  
 
Serological methods 
Serological methods of investigation play a tremendous role in CCHF diagnostics. 
They are based on the detection of IgM and IgG antibodies against the virus or 
detecting the virus antigen. The best time for blood withdraws for serological 
investigation for antibodies against CCHFV is after fifth day illness. As with all viral 
infections, the diagnostic of CCHFV infections should be done with in-depth 
consideration of day of illness, possible virus circulation and time of antibodies release 
(108), as the virus could be detected within the first six days after the disease onset 
(116). The antibody detection in blood of sick patients not only identify the antibodies 
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against the pathogen, but also an ominous sign of the disease severity (95). It was 
noted that among the survivors, antibodies appeared in the early phase of diseases 
(116).  
The best commercial kits for detecting antibodies are IFA, Euroimmun (Luebeck, 
Germany ) and IgM and IgG n ELISA Vector-Best ( Novosibirsk, Russia) and are 
recommend in geographic regions close to Kazakhstan (117). (www.canada.ca).  
 
2.1.2.7 Epidemiology and vectors of CCHFV 
 CCHF can develop in a severe disease only in humans(75). Despite the developing 
of antibody response and viremia, the signs of CCHF never appear in animals, except 
for newborn mice (118)(67)(69). The infected animals play a substantial epidemiological 
factor to be infected by CCHF as they do not have signs of the disease. Humans can be 
infected through tick bites, contact with infected blood and tissue of animals, 
consumption of raw milk (119). Moreover, often nosocomial infections are happening, 
when medical personnel and members of family contact with biological fluids. The 
CCHF virus transmission through sexual contacts was described in Russia(120). 
However, tick plays a considerable role in virus transmission of CCHFV and circulating 
in nature. The virus distribution reflects the distribution of the main vector of CCHF, tick 
spp. Hyaloma (121)(122). However, the tick spp. Rhipicephalus, Dermacentor, 
Haemaphisalis could be vectors for CCHFV (122). The ecology of the ticks spp. 
Hyaloma showed that the main hosts of its larvae and nymphs are birds that feed on the 
earth, mainly rooks. The imago of tick spp. Hyaloma parasite on cattle, horses, sheeps 
and goats. Animals (cows, goats, sheep, hares, hedgehogs) could be a reservoir of 
CCHF virus. The infected animal the viremia could infect parazatiting on them ticks. The 
features of the structure of tick spp. Hyaloma could explain that these species are 
adaptive for dry and hot weather because of the structure of cuticle and Haller's organ, 
the glands of Haller's organs providing good moisturizing(123). Also, it could explain the 
tick activity from April till the end of July and distribution of these species of ticks in the 
Southern part of Kazakhstan, where the weather temperature in summer achieves 50 0 
C(124) and it explains that these species of ticks circulate in Oriental, Palearctic and 
several parts of Sub-Saharan Africa (122).  
According to an epidemiological study based on statistical estimation, five countries 
(Turkey, Iran, Afghanistan, Tajikistan, and Pakistan) have the highest evidence of 
CCHF presence. 
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Moreover, under the high risk the countries of Central Asia, South-west of the 
Russian Federation, the regions of Sub-Saharan Africa and Central Africa. The CCHF 
presence could be active for such countries as Syria, Iran, Iraq, Romania, Moldova, and 
Ukraine. Moreover, the CCHFV affected territories are expanding due to climate 
change, increasing of temperature level and decrease in precipitation. All these weather 
conditions create favorable conditions for tick spp. Hyaloma (the main vector of CCHFV) 
surviving in case of tick transporting by birds(94)(125) 
 
2.1.2.8 Crimean-Congo Hemorrhagic Fever in Kazakhstan  
Geographically Kazakhstan consist of 14 oblasts (areas). Three oblasts are endemic 
for Congo-Crimean Hemorrhagic Fever. These oblasts are Kyzylorda oblast, Turkestan 
oblast (the former The South Kazakhstan oblast) and Jambyl oblast (see figure 3). 
These oblasts share the border with the endemic for Crimean-Congo Hemorrhagic 
Fever country as Uzbekistan and Turkmenistan where were several outbreaks of 
Crimean-Congo Hemorrhagic Fever were registered during the Soviet Union Era (67) 
and the evidence of Crimean-Congo Hemorrhagic Fever presence is also reported 
nowadays, however the lack of data is available (126). 
 
 
Figure 3. CCHF endemic oblasts (areas) in Kazakhstan 
 
 
 
31 
 
 
According to Dobritsa P.G, 1965, 1975 the first cases of CCHF were registered in 
1948 in the South of Kazakhstan oblast, later the clinical cases of CCHF were 
registered in Kyzylorda oblast. And only in 1982 in Jambyl oblast a natural focus of 
CCHFV was identified by the scientific workers of Kazakh Scientific Institute of 
Epidemiology and microbiology of infectious diseases after the CCHF outbreak. 
However, this disease was known on the territory of Kazakhstan since ancient time and 
named as “Kokala” in translation from Kazakh language is “colorful body” because of 
hemorrhagic syndrome (Genis et al., 1971). This infection was well known among the 
population of Central Asia. In Uzbekistan, it was named as “kara-halak”, that means a 
black death, in Tadjikistan ( Kolachev,1945; Blyaher et al., 1971) CCHF was known 
under the name “Hungibta” or “Hunimuni” and it means “bleeding from the 
nose”(Aristova V.A., et al.,1973; ). In 1944 was described in Central Asia by Sipovskii 
V.V.. He investigated the pathological material of people who died from the diseases 
with hemorrhagic syndrome. Later the same outbreak of fever with serious hemorrhagic 
syndrome was in Uzbekistan, Tajikistan and Turkmenistan. In 1947 the fever with 
serious hemorrhagic syndrome got the name “Central Asian hemorrhagic Fever”. 
Central Asian Hemorrhagic Fever as separated nosological form till 1967. In 1967 by 
Leshinskaya and Chumakkov was proved that Central Asian hemorrhagic Fever and 
Crimean Congo Hemorrhagic Fever are the same disease (Leshinskaya, 1967). 
The clinical presence of Crimean-Congo hemorrhagic Fever in Kazakhstan doesn’t 
have any different features. Crimean Congo Hemorrhagic fever is developing through 
the incubation that is usually lasting from three to seven days (19) and following by the 
pre-hemorrhagic phase. But according to some observations made on territory of 
Central Asia and the South west parts of Russia there are some differences. The 
incubation time is lasting for 7-12 days according to Kolachev A.A. ( Kolachev et al., 
1949), by the data of Leshinskaya it could be 3-12 days (Leshinskaya,1967), and by 
Lazarev V.N. it is lasting 1-14 days. But in 94.2% of patients the incubation time period 
does not exceed 10 days, 72.1% patients had two-four days of incubation period 
(Lazarev V.N. Crimean Hemorrhagic Fever in Rostov Oblast, thesis, Moscow, 1973). 
Annually 11 cases of Crimean-Congo Hemorrhagic Fever are registered in endemic 
oblasts (areas) of Kazakhstan(127). Usually, the CCHF cases are registered from April 
till September during the tick activity. Approximately up to 37.8% of all registered cases 
occurred in May and June (128).  
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According to reports of Kazakh Scientific Center of Quarantine and Zoonotic 
Diseases, Crimean-Congo Hemorrhagic Fever is characterized by the dispersion of 
natural foci. Long-term epidemiological observations and the data of virological and 
serological investigations demonstrates, that vectors of Crimean-Congo Hemorrhagic 
Fever Virus are different. In the southern (Turkestan oblast and former the South 
Kazakhstan Oblast) in piedmont areas, the foci of Crimean-Congo Hemorrhagic Fever 
Virus “occupies” small territories and the main vector is H. anatolicum. H. anatolicum is 
mostly parasitic on livestock. On the livestock from this region, ticks H. anatolicum, was 
found in all its life stages from nymph till imago. The natural foci of Crimean-Congo 
hemorrhagic Fever located in flood plain areas as the territories adjusted to Syrdaria, 
the main vector is as H. detricum and H. asiaticum could be as well. A feature of H. 
detricum is that hares, gophers and other rodents are involved into a feeding process. 
The most active circulation of Crimean-Congo Hemorrhagic Fever Virus is in deserts 
Karakum, Moyinkum, Sarykum, Saryesik Atyrau and Rin desert. The main vector of 
Crimean-Congo Hemorrhagic Fever Virus in these regions is H.asiaticum. In these 
regions the virus circulation is maintained between vectors H.asiaticum and hosts. The 
hosts are camels, livestock, saigas and rodents. The natural foci of Crimean Congo 
Hemorrhagic fever in these areas are the most dangerous for human(128) (Abdikarimov 
et al., 1995). In general, the endemic areas have a continental climate, a very hot in 
summer with a lack of humidity that is very favorable for ticks Hyaloma asiaticum, 
Hyaloma anatolicum, Hyaloma suspense and Hyaloma marginatum. All these ticks are 
presented in endemic region for Crimean-Congo Hemorrhagic Fever. The density of 
ticks are high in these areas, more than 1500 imago ticks could be collected from a 
single animal (127). Also due to different landscape in Kazakhstan, there is a wide 
range of tick species. The antigen of the virus is also presented in ticks spp. 
Dermacentor, spp. Rhipecephalus. The wide variety of ticks that could be a potential 
vector of Crimean-Congo hemorrhagic Virus observed in Kazakhstan is reflected the 
research that 27 ticks taxa could be associated with Crimean-Congo Hemorrhagic 
Fever Virus (Hoogstral, 1979) (12).  
 In 2015 and 2012 the evidence of CCHFV circulation was also identified in not 
endemic regions for CCHF in tick spp. Dermacentor in Almaty oblast, in ticks. 
Rhipicephalus pumilio in the West Kazakhstan oblast and in ticks H. asiaticum and R. 
schulzei in Aktobe oblast (see figure 4), hence the findings demonstrates that Crimean-
Congo Hemorrhagic Fever virus distribution could be expanded over the officially 
recognized Crimean Congo Hemorrhagic Fever endemic areas (see figure 4). But it 
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could be explained that the endemic areas for Crimean-Congo Hemorrhagic Fever were 
established according to officially registered Crimean -Congo hemorrhagic Fever cases 
that have clinical features as hemorrhages. Nevertheless the clinical cases without 
hemorrhages or not hemorrhagic forms are usually remain undiagnosed (127). 
According to Abdikarimov et al., 1995 the not hemorrhagic form of Crimean-Congo 
Hemorrhagic Fever could be up to 9 %, however this number could be exceeded. 
Therefore, the question of true distribution of Crimean-Congo hemorrhagic Fever is 
under the big debates. And the knowledge on the proportion of patients with possible 
Crimean-Congo Hemorrhagic Fever infection among the patients are suffering from the 
fever, the true prevalence of Crimean-Congo Hemorrhagic Fever Virus in vectors and 
the circulation genotype of Crimean-Congo hemorrhagic Fever Virus is necessary. The 
necessity is important because the knowledge will improve the approaches in 
diagnostics of Health Care of Kazakhstan and surveillance system over this disease. 
But due to Kazakhstan is also one of the rapid developing countries in the Central Asia 
with the increased growth of international business opportunities, tourism and multi-
national military deployment in neighboring countries, there are an increased demand 
for epidemiology and molecular biology of Crimean-Congo Hemorrhagic Fever and 
other arboviruses(7). The aim of this thesis to discover these questions.  
 
 
Figure 4. The evidence of CCHFV circulation in not endemic oblasts in Kazakhstan 
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3 CHAPTER 3 
3.1  Rationale and objectives 
3.1.1 Rationale of the study 
 Kazakhstan is one of the countries in Central Asia with the rapid growth of the 
Economy. The developing and establishment of oil and mining companies make this 
country interesting for international business. Every year hundreds of employees visit 
the sites of these manufacturers (www.forum-astana.org). Moreover due to the 
increasing density of population, developing the local and international tourism and 
urbanization the risk to be exposed by zoonotic infections as bacterial and viral as well 
is increasing (4). The awareness of being exposed by dangerous pathogens is 
reasonable. Kazakhstan has one of the biggest territories in the world, hence it the 
diverse climate range from the dry and hot in the south and cold with a high level of 
humidity in the north. The landscapes are desert, semi-desert, mountains, forests. All 
these environmental factors are favorable for different species of mammals that could 
be a reservoir for different pathogens. It is known that territory of Kazakhstan is endemic 
for dangerous zoonotic infections as Plague, Anthrax, Tularemia and zoonotic viral 
infections as Tick-Borne encephalitis and Crimean-Congo Hemorrhagic Fever. For 
example, more than 40% of the territory of Kazakhstan is favorable and susceptible to 
Plague, Anthrax, and Tularemia. Up to 40% of the territory is endemic for Tick-borne 
encephalitis and Crimean-Congo Hemorrhagic Fever(61). Annually, the incidence of 
TBE and CCHF are reported. Despite the existence of endemic areas for CCHF and 
TBEV and incidence of these infections, there is a lack of knowledge on these infections 
(7). There is no data on the prevalence of CCHFV and TBEV in vectors based on 
modern molecular methods of investigations in endemic and not endemic areas. In 
terms of the activation of old foci of TBEV, especially in not typical landscape and 
vectors, the question of approvement of molecular diagnostics of TBE cases is required. 
Moreover, there is no data or lack of data on circulating genotype of CCHFV and TBEV. 
Despite the fact that the possible cross-reactivity with other flaviviruses could be, 
especially in a country endemic for other flaviviruses as Kazakhstan (6) (148).  
The diagnostics of CCHF and TBE even in reference laboratories is based on 
serological methods of investigations, mainly by ELISA.  
The scientists over the world named Kazakhstan as "White spot" (in personal 
communication) as no new modern data based on molecular methods of investigations 
are available. Thus, due to the involvement of Kazakhstan in globalization, there is 
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currently a high demand for the knowledge over these diseases. The knowledge of it is 
a fundamental basis not only for an accurate diagnostic but also for biosafety and 
biosecurity measurements as well. 
Moreover, the role of these infections as a cause of fever in proportions of patients 
suffering from the fever in endemic and not endemic areas is still unknown. The few 
data are only available from the medical hospitals, but the data mostly based on clinical, 
epidemiological features of the diseases. 
Despite the annual incidence of CCHF and TBE, and surveillance system over these 
diseases in Kazakhstan, the standard operating procedures over the CCHF and TBE 
diagnostics were not developed. 
This thesis aims to improve the exact data on the prevalence of TBEV and CCHFV in 
vectors of investigated regions. 
 To understand the prevalence of CCHF and TBE in proportions of patients who 
suffer from fever in an endemic territory and not endemic territories as well. Also, this 
thesis is targeted to understand the actual distribution of patients with CCHF. In terms of 
the authorities of Kazakhstan gives the high rate of lethality, there are big debates over 
the not diagnosed CCHF cases. Thus, this project study was aimed not only to find out 
the role of CCHF as a causative pathogen of fever but also to reveal the proportions of 
patients with CCHF who remain undiagnosed. 
One of the principal aims of this thesis is to discover the circulating subtypes of TBEV 
and CCHFV as well. The molecular data over this disease is a fundamental basis to 
improve the level of knowledge over the arboviral zoonotic diseases not only in 
Kazakhstan but also in surrounding territories. 
Not a secondary target of this project study was developing and implementing the 
Standard operational protocols (SOPs) over the laboratory diagnostics (ELISA of IgG 
and IgM, PCRs,). Also, SOPs over the laboratory work with highly pathogenic viruses 
and material containing the viruses (Ticks homogenization, Rodent tissue 
homogenization, Infectious samples inactivation) in Biosafety level 2 laboratories and in 
the Biosafety level 3 were laboratory developed respectively. 
The results of this project study will improve the level of knowledge of the distribution 
of TBE and CCHF, the surveillance of these infections in Kazakhstan. As CCHF does 
not have any effective vaccine, and as TBE does not have any specific treatment, the 
surveillance over these diseases play a substantial role. The knowledge over the 
circulating strain could help as in the treatment of patients and for biosafety 
measurements as well. The methods of diagnostics and protocols of molecular 
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investigations used during the project study could be successfully implemented in 
diagnostic protocols of target infections and positively influence the diagnostic and 
surveillance system of the Health Care of Kazakhstan 
 
3.1.2 Objectives of the study 
 In general, the objective of this study to figure out the prevalence of target 
arboviruses in vectors and find out their role as a causative agent of fever.  
The specific objectives are outlined below: 
 To determine the vectors of CCHFV and TBEV 
 To calculate the prevalence or minimum infection rate of CCHFV and TBEV in 
vectors in an endemic and not endemic region as well. 
 To detect the circulating genotype of CCHFV and TBEV. 
 To determine the proportion of CCHF infection in patients with fever  
 To determine the sociodemographic risk factors of being exposed by CCHFV in 
Kazakhstan 
 To determine the epidemiological risk factors of being exposed by CCHFV in 
Kazakhstan  
 To determine the proportion of patients with recent or acute CCHF infection in 
endemic areas. 
 To calculate the proportion of patients with recent or acute CCHF infection in not 
endemic areas. 
 To calculate the proportions of patients with recent TBEV infection in endemic 
and not endemic areas. 
 To work out the standard operational protocols (SOPs) for diagnostics of highly 
pathogenic viruses as TBEV and CCHFV and to implement SOPs into the   
 To update the protocols of the molecular methods of diagnostics to the platforms 
in Kazakh laboratories and to implement them for diagnostics of TBEV and CCHFV, 
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4 CHAPTER 4 
4.1 Methods  
This project study consists of two studies as tick study and serological study as well. 
During the tick study the ticks from pilot regions have investigated the presence of 
TBEV and CCHFV, and during the serological study, the sera from patients were 
investigated for target infections. The methods are in detail outlined below.   
 
4.1.1 Tick study 
4.1.1.1 Tick collection 
 Ticks were collected by flagging at 32 locations of the two selected oblast (Almaty 
and Kyzylorda oblasts) in May and June in 2015. Sampling was chosen according to 
routs of tick collection established by entomologists of the Scientific Practical Center for 
Epidemiological Expertise and Monitoring (SPCEEM). The tick collection was conducted 
in May-June 2015, during the peak activity of ticks. For each sampling site, GPS data 
were noted. The collected ticks were morphologically identified and sorted by gender 
and stage of development. Collected ticks (n=2341) were sorted into pools in laboratory 
biosafety level 2 of SPCEEM. Each pool contained five imago ticks of the same species.  
Samples were collected in Almaty oblast in three districts, Almaty district, Tekeli 
district and Yenbekshikazakh district at 35 sites, respectively. In Kyzylorda oblast ticks 
were collected in three districts Zhanakorgan district, Shiely district and Syrdariya 
districts at 18 sites, respectively.  
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Kyzylorda oblast 
 
Almaty oblast
 
Figure 5. The pilot oblasts (areas) of project study, Almaty and Kyzylorda oblasts 
 
4.1.1.2  Room regime 
 According to the recommendation of the Laboratory Safety (103), before and after 
the work in a laboratory at SPCEEM and KMNU, all work surfaces were disinfected by 
Hypochlorite 0.5%-1% or liquids contain hypochlorite. All manipulations conducted in 
biosafety cabinet A2. Before the transportation the material, the tubes were placed in 
the second box and disinfected and only then were transported.   
Work with RNAs requires proper disinfection against RNAses. As RNAses are 
ubiquitous and destroy RNA. For this purpose, we clean all surfaces before the work 
with RNAse remove liquid.  
 
4.1.1.3  Tick homogenization  
During the tick sorting disposable tools were used in terms of cross-contamination. 
All steps were conducted in biosafety cabinet A2. Before the homogenization, the 
collected ticks were sorted in pools by gender and stage of development (see 4.1.1.). 
The ticks were pooled into a previously prepared Eppendorf safe-lock 2.0 tubes 
containing two ceramic beads and 1 ml medium 199 (suitable for cell cultures) was 
added. Each pool was homogenized by a Tissue Lyzer (Qiagen, Germany). Before the 
homogenization, Eppendorf safe-lock 2.0 tubes containing the ticks were placed into the 
pre-cooled adaptors. The pre-cooled adaptors are necessary, as it prevents increasing 
the temperature during the shaking and friction. In a case of a not wholly tick 
homogenization, the procedure was performed again. After the homogenization, the 
homogenates were used for further RNA extraction or the tubes with homogenates were 
39 
 
placed into the secondary packaging (box). The secondary packaging was disinfected 
by hypochlorite 0.5%, put into the plastic bag and placed into the freezer at -20. The 
place was disinfected according to the SOP “Room regime”.  
 
4.1.1.4  RNA extraction 
The RNA extraction was conducted with the commercially available "QuiagenRNA 
mini kit." The kit was used according to the manufacturer’s instructions. RNA extraction 
was divided into two steps. The first step is Lysis and second the QIAamp viral mini spin 
procedure. 
The Lysis step. 
The lysis step was crucial for a sample inactivation. 5.6 µl carrier RNA and 560 µl of 
AVL buffer were filled into Eppendorf safe-lock tubes 2.0 and 140 µl of a supernatant of 
the sample (homogenate) was added. This step leads to a sample lysing under the 
denaturing conditions provided by the AVL buffer supplemented with Carrier RNA. 
Moreover, the Buffer AVL inhibits RNAses and stabilizes viral RNA. At the same time, 
the carrier RNA improves binding the viral RNA to QIAamp membrane and reduces the 
chance of viral RNA degradation.  
The QIAamp viral step.  
Into the tubes with samples 560μl ethanol (96-100%) was added. Then the sample 
was shaken carefully for 15 sec (vortex) followed by a short centrifugation step to 
remove liquid from the top of the tubes. From the lysed probe 630μl was added on the 
QIAamp Mini Spin Columns without touching the column material and centrifuged at 
6000g/8000g for one minute. The eluate was discarded. After the sample was 
transferred into the QIAamp Mini Spin Columns, washing with buffer AW1 and Buffer 
AW2 was conducted. AW1 contains the guanidine salt; this salt is a strong denaturant. 
The RNAses are the most durable proteins and require the guanidine for denaturation 
(128). So AW1 is used to denature the proteins and denaturized protein could pass 
through the filters and therefore increase the quality of RNA. This step was following by 
the centrifuging at 8000 g and the washing step with AW2 buffer. AW 2 Buffer is 
necessary to remove the guanidine salt (129).  
Thus, the washing step with AW1 and AW2 completely removed the residual 
contaminants. The washing with 500µl of AW1 and then with 500 µ AW2, following by a 
final centrifuge step at 14000 g. Elution of the RNA was done with by 40 µl of Elution 
Buffer into sterile PCR clean1.5 ml tubes. The eluting step was conducted by 
40 
 
centrifuging twice for xx minutes at 6000 g 80 µl of eluted RNA was aliquot into 20 µl in 
1,5 Eppendorf tubes and stored at -800C.  
 
4.1.1.5  TBEV RT –qPCRs and target E gene conventional PCR 
The extracted RNAs from the tick’s homogenates (see 4.1.4) were screened for the 
detection of TBEV RNA. TBEV RNA was detected by reverse transcription (RT)-qPCR 
(47). 5µl of TBEV RNA was amplified in 25 µl RT-qPCR mixture QuantiTect Virus kit 
(Qiagen, Germany)) of 0,2 µM of each primer, forward (5’-gggCggTTCTTgTTCTCC), 
reverse (5’-ACACATCACCTCCTTgTCAgACT) and 0,16 µM of hybridization probe (5’-
6FAM-TgAgCCACCATCACCCAgACACA-TMR) with reagents according to the 
instructions and protocol as it was described previously (47).  
Extracted strains of Langat virus (Acc. Number NC_003690) was used as positive 
control and distilled water as negative control.   
To acquire the E-gene the positive samples of the RT qPCR were used to do a 
conventional RT PCR with primers targeting the E gene region (1632 nt). Briefly, 5 µl of 
RNA was amplified with 0.2 µM of reverse and forward primers and SuperScript ΙΙΙ high 
fidelity RT PCR System with Platinum Taq DNA Polymerase (Invitrogen) in a final 
volume of 50 µl (129). 
The initial amplification of the cDNA was performed at 50°C for 45 min, then a step of 
denaturation at 94 0C for 5 min was carried out. The amplification was conducted for 40 
cycles at 94 0 C for 30 sec, 60 0C during 30 sec and 2 min at 68 0C. A final extension 
step at 68 0 C for 10 min was done.  
. 
Table 2.Primers used for E-gene conventional PCR 
Region/District Forward Revers 
Tekeli samples  947 A+ 947B 
5’TCCTCTgCCTggCTCCggTTTAT
g + 
5’TCTTgTgCCTggCTCCggTTTATg 
R2579 
5-
TCTTgTgCCTggCTCCggTTTAT
g 
Talgar samples 947 A+ 947B 
5’TCCTCTgCCTggCTCCggTTTAT
g +5’TCTTgTgCCTggCTCCggTTTATg 
R2579 
5-
TCTTgTgCCTggCTCCggTTTAT
g 
Yenbekshikazakh 
samples 
 
9947 A+ 947B 
5’TCCTCTgCCTggCTCCggTTTAT
g +5’TCTTgTgCCTggCTCCggTTTATg 
 
R2579 
5-
TCTTgTgCCTggCTCCggTTTAT
g 
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885 5’-
ggTTACCgTTgTgTggTTgACC-3’ 
R2579  
5-
TCTTgTgCCTggCTCCggTTTAT
g 
 885 5’-
ggTTACCgTTgTgTggTTgACC-3’ 
R 2605 5’- TTT CCT TTA Tgg 
CCg ATg CTA gCg -3’ 
 
The amplified products were run in agarose 1.5% gel and visualized by Gel Red® 
under illumination of ultraviolet light. 
 
4.1.2 Serological study  
 
4.1.2.1 Ethical approval and informed consent administration 
The study protocol was reviewed and approved by both ethical committees, the local 
committee that is located at Kazakh National University named after S.D. Asfendiyarov, 
in Almaty, Kazakhstan and the ethical committee at the Ludwig-Maximillians Universität, 
Munich, Germany. Because Kazakhstan is a bilingual country, the informed consent 
form was translated into two languages Kazakh and Russian. The consent form was 
given in Kazakh or Russian language; this depended on national originality and ability to 
think and understand Kazakh or Russian languages. Before enrolment in the study, a 
volunteer carefully explained the objectives of the study, the anticipated risks, the 
voluntary nature of participation, about the rights of refusal at any step of study without 
recrimination to a volunteer.   
According to state regulations, adolescents starting from 15 years old are 
hospitalized in medical facilities for adults. In a case of 15 years old volunteer, the 
consent form was provided as for a patient and his parents or his guardians as well. 
(See Annex)  
 
4.1.2.2  Questionnaire 
A structured interview-administered questionnaire was provided to every patient (a 
volunteer). The questionnaire consists of six modules reflecting the sociodemographic, 
education and work, living and housing, livestock, vector habitat factors, and clinical 
symptoms. The modules were based on risk factors for target infections identified in the 
literature review. However, the questionnaire was constructed in terms of risk factors of 
several diseases that could be a cause of fever of unknown origin as viral and bacterial 
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as well. The questionnaire was designed several zoonotic infections such as infections 
with TBEV, CCHFV, Hantaviruses and Rickettsia (See Annex 7). 
 
4.1.2.3 Administration of questionnaires 
Trained medical personnel administered the questionnaire. Trained medical 
personnel entered the collected responses into the questionnaires. Participation in the 
census was voluntary. A volunteer had the rights do not answer the questions if he felt 
difficulties in answering. The questionnaires were checked for the completeness by the 
same medical personnel. The blood withdraw was done after the questionnaire session. 
Due to Kazakhstan is a bilingual country, the questions, and possible responses were 
provided in Kazakh and Russian languages 
 
4.1.2.4 Description of variables 
 Hospital ID number: a hospital Identification number assigned a volunteer. It is an 
abbreviation of the city or district.  
 Participant ID: A Participant Identification number assigns volunteers. It was a 
letter and a four-digit number starting in 0001. No volunteer was received more than 
one number. 
 Sex of participant: is gender and categorized as (1) Male and (2) Female. 
 Name of Study site: is an area where a study was conducted and categorized as 
(1) Almaty region, (2) East Kazakhstan, (3) North Kazakhstan, (4) West Kazakhstan and 
(5) Kyzylorda. 
 When were you born: describes a date of birth. 
 How old are you: describes the age in years. 
  Present marital status: describes the marital status of the volunteer and 
categorized as (1) Single, (2) Currently married with one spouse, (3) Married with two or 
more spouse, (4) Not married, living with permanent partner, (5)Separated/divorced, (6) 
Widowed,(7)Declined to answer,(8)Other. 
  Place of birth: describes the country of birth and categorized as (1) Kazakhstan, 
(2) Kirgizstan, (3) Uzbekistan, (4) Other countries.  
  The oblast of Kazakhstan a patient born: describes the oblast (administrative 
area) where the volunteer was born. 
 Living City/Town/Village describes the current address of a volunteer. 
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 Since when have you been living in this city/Town? Village?: describes the 
cumulative years of living in the city or town or village and categorized as (1) Always 
lived in this place, (2) Years 
 Have you made any trips from your place of residence within the last month: 
describes the possible trips and categorized (1) No (2) Yes, specify 
  The contact with wild animals: describes the possible contact with the wild 
animal and categorized as (1) Yes and (2) No  
  Bites by ticks, mosquitoes, insects or wild animals within the last month: this 
describes the possible bites of ticks, mosquitoes or wild animals and categorized as (1) 
No, (2) Yes, specify. 
 The highest level of education: This variable describes the education status of a 
volunteer and categorized as (1) Still in school, (2) Primary finished, (3) Primary 
unfinished, (4) Secondary finished, (5) Any higher education, (6) Adult education, (7) 
Have no formal education, (8) Declined to answer/Don’t know.  
 The current occupation: this variable describes the current activity and 
categorized as (1) Pupil, (2) Farmer/Peasant/plants, (3) Farmer/Peasant/animal, (4) 
Farmer/Peasant/forestry, (5) Keeping the house, (6) Unskilled laborer, (7) Skilled 
laborer, (8) Local or long distance driver, (9) Administrative or academic professional, 
(10) Businessman/woman, (11) Nurse / Physician / Clinician / Pharmacist, (12) 
Unemployed, (13) Declined to answer, (14) Other  
 How long have you been working in your current occupation: Describes the 
cumulative years of working at the current position in years. 
 How often do you usually work in the gardens and fields: Describes the 
frequency of working in the gardens or fields, categorized by (1) Yes, always, (2) Yes, 
often, (3) Yes, occasionally, (4) Yes, but rarely, (5) No, never 
  Ability to read a letter or newspaper easily, with difficulty, or not at all: describes 
the literacy level of a volunteer and categorized by (1) Easily, (2) With difficulty, (3) Not 
at all, (4) Declined to answer. 
  The total cash income of your household per year: describes the average 
income of a volunteer 
 The number of people regularly eat together in the household: describe the 
number of family members of a volunteer eat and live together. 
 The type of a flat or house: describes the current place of living of a volunteer 
and categorized by (1) Well-equipped, (2) Poorly equipped city apartment, (3) Private 
well-equipped house, (4) Poorly equipped house and (5) other 
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 The storage of bulk products: describes the keeping of products and categorized 
by (1) In bags, (2) In casks, (3) Other 
 The water source: describes from what source a volunteer gets the water and 
categorized by (1) City water pipe, (2) Rural water pipe, (3) Blow well, (4) River 
 The consumption of raw milk or raw milk products from animals: describes the 
eating of raw milk product and categorized by (1) No, (2) Yes, from which animal  
 The types and number of animals in a household: describes the animals in a 
household and categorized by the type of animal by (1) Cattle and amount. 
 Animal’s disease: describes if an animal in a household has a disease and 
categorize by (1) Yes, (2) No 
 Animal’s disease symptoms: the symptoms are described and categorized by (1) 
Unusual movement, (2) Respiratory symptoms, (3) Gastroenterological symptoms (4) 
Lesions, (5) Others 
 The death among animals: describes the cases of death among the animals and 
categorized by (1) Yes and (2) No. 
 Contact with death animals: this variable describes the possible contact with 
dead animals and categorized as (1) Yes and (2) No 
 How often direct contact to the following animals was: This variable describes the 
contact frequency with animals, the frequency estimates from 1 as the Always/daily, 2 - 
Most of the times, 3 – Rarely and 4 – Never. The determined animals are Cattle, Horse, 
Goats, Sheep, Pigs, Cats/Dogs, and Poultry.   
 The handle with raw meat: This variable describes the manipulation with raw 
meat as slaughtering, butchering, preparing for cooking and categorized by (1) Yes, 
always, (2) Yes, most of the times, (3) Yes, but barely, (4) No, never 
 How often rats/ mice or bat poop was noticed: This variable describes the 
frequency of the notice of rats/mice or bat poop. This variable categorized by (1) 
Always, (2) Most of the times (3) Rarely, (4) Never. 
 How often the rats/mice or bats were killed in the house: The variable describes 
the contact frequency with them and categorized by (1) Always (2) Most of the times (3) 
Rarely (4) Never.  
 The bird nests in the roof: this variable describes the evidence of bird nests on 
the roof and categorized by (1) Yes, (2) No, (3) Do not know 
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 Bats live in your house or trees around the house: This variable describes the 
evidence of bats around the house, and it is categorized by (1) Yes, (2) No, (3) Do not 
know.  
 The location of the house: describes the current placement of the house of a 
volunteer and categorized by (1) Rural area, (2) Urban area 
 The type of the ground around the house: describes the surrounding of the house 
and categorized by (1) Tarmac, (2) Sand, (3) Dirt 
 The look of the vegetation around the residence: This variable describes the 
possible vegetation around the house and categorized by (1) Dense plantation/forest, 
(2) Larger grass fields, (3) Occasional bush agricultural fields, (4) Swamp, (5) Lake, (6) 
Forests, (7) Others, specify. 
 The water close to your residence : This variable describes the possible water 
source and categorized by (1) Puddles after heavy rain, (2) Containers for collecting 
water, (3) Lake, (4) Steam, (5) Gully in urban area (7) No, never, (8) Don’t know 
 How many months per year the water around the residence is: this variable 
describes the cumulative months the quantity of months the water is around the house 
 Beginning of clinical symptoms: describes the time of the disease onset and 
categorized as (1) More than five days ago, (2) Less than five days ago 
 The symptoms: describes the clinical symptoms of the disease and categorized 
as (1) Fever, (2) Headache, (3) Meningism, (4) Weakness of muscles or joints,(5) 
Muscle pain or recurrent cramps, (6) Pain on swallowing, (7) Joint pain, (8) 
Stomach/abdominal pain/cramps,(9) Back pain, (10) Earache, (11) Cough, (12) 
Difficulties in speaking, hearing or seeing, (13) Seizures/epilepsy, (14) Difficulties in 
breathing, (15) Rapid breathing, (16) Sore throat, (17) Congestion of nose, (18) 
Enlarged lymph’s nodes, (19) Icterus. 
 Body temperature: describes the fever level and categorized as (1) Less than 
37.50C, (2) More than 37.50C. 
 Duration of high body temperature: describes the cumulative days of fever and 
categorized as (1) Less than three days and (2) 3 days and more 
 Blood pressure: describes the level of blood pressure and categorized as (1) 
Normal, (2) Hypotension, (3) Hypertension. 
 Pulse rate: describes the rate of heartbeats and categorized as (1) Less than 80, 
(2) 80-100, (3) More than 100 
 Skin condition: describes the skin lesions and categorized as (1) Exanthema, (2) 
Ulceration, (3) Edema, (4) Others 
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 Stool: describes the changes in stool and categorized as (1) Diarrhea, (2) Blood 
in stool, (3) Bright stool, (4) Other 
 Urine: describes changes in urine and categorized as (1) Blood in urine, (2) Pain 
on urinating, (3) Dark urine, (4) Low urine volume, (5) Other 
 Medications: describes a volunteer took the medicines and categorized as (1) 
Antipyretics, (2) Antirheumatics, (3) Antibiotics, (4) Other. 
 Duration of therapy: describes the cumulative days of therapy  
 Similar illness in the family or surroundings: describes the presence of similar 
symptoms within the family and categorized as (1) Yes, (2) No. 
 
4.1.2.5 Sera collection  
Blood was collected from patients on the first day of admission to the target hospital 
and after 10 or 14 days. The blood was collected from April to October in 2014 and 
2015 during the season of tick's activity and from patients according to the criteria of 
inclusion and exclusion. Into the study, only patients with were older than 15 years old 
and with fever, more than three days and ear measured were involved. Moreover, 
patients had to be residents of the investigated area. The patients with confirmed 
infectious diseases, rheumatological diseases, and rhinitis or without no gained second 
serum were excluded from the study. The sera were collected in nine target hospitals of 
Almaty oblast and four hospitals of Kyzylorda oblast. Almaty oblast hospitals were the 
city hospital of infectious diseases in Almaty city, the regional infectious hospital in 
Kaskelen city, the regional hospital of infectious disease in Shelek region, in Kapchagay 
city, in Yessik city, the regional hospitals in Kabanbay, Taldykorgan, Usharal, and Tekeli 
cities. In Kyzylorda oblast; patients were enrolled in the four regional hospitals of Shiely, 
Syrdariya, Zhanakorgan, and Kyzylorda districts. 
Patients samples were only taken after patients filled in a consent form (In Russian or 
Kazakh language) before the blood taking was initiated (see Annex 6). Moreover, before 
the procedure, the patient was informed that participation in the study is entirely 
voluntary and that they will not receive any financial compensation amount of blood 
drawn was approximately 20 milliliters covered by coagulation activator as we needed 
to get the serum without fibrinogen and any blood cells. In maximum, four phlebotomy 
attempts were made per person. Before the initiation of phlebotomy, the patient was 
informed about possible risks of procedure of phlebotomy even a small amount of blood 
was withdrawn. The patient was informed about the possible risk of phlebotomy as 
ecchymosis, localized skin infection, thrombophlebitis, and dizziness, syncope during or 
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after the procedure. The procedure was conducted by trained medical personnel in 
target hospitals. After the blood was withdrawn, the blood was centrifuged, and the 
serum in the supernatant was transferred into cryotubes and saved at -200 C. The 
scheme of sera investigation (see 4.2.7). 
 
4.1.2.6 Sera inactivation 
According to the regulations on biosafety or Laboratory Safety, by the Public Health 
Agency of Canada (PHAC, www.canada.ca) before the initiation of a serological and 
molecular investigation, an aliquot of 140 µl of sera was inactivated at 56 0C for 30 min 
in a water bath before investigation. The heating was experimentally proved as a safe 
method of inactivation of possible CCHFV and TBEV viruses (43).  
For molecular investigations, additionally to the heating, the AVL buffer was used 
(Qiagen, Germany which contains a chaotropic salt and is highly effective in inactivation 
of CCHFV and TBEV (41)(107). During this step into the Eppendorf safe-lock tubes, 2.0 
filled with 5.6 µl carrier RNA and 560 µl of AVL buffer were filled into Eppendorf safe-
lock tubes 2.0 and. Then 140 µl of the supernatant of the sample (homogenates or 
serum) was added. This step leads to a sample lysing under the denaturing conditions 
provided by the AVL buffer supplemented with Carrier RNA. Moreover, the Buffer AVL 
inhibits RNAses and stabilizes viral RNA. At the same time, the carrier RNA improves 
binding the viral RNA to QIAamp membrane and reduces the chance of viral RNA 
degradation. The sera inactivation by heating for serological methods of investigation or 
lysis step by AVL buffer for further molecular methods of investigation were conducted 
at SPCEEM, Almaty, according to all biosafety regulations and recommendations.  
 
4.1.2.7 RNAs extraction  
The RNA extraction was conducted with the commercially available "Quiagen RNA 
mini kit." RNA extraction was divided into two steps. The first step is Lysis was 
conducted at SPCEEM (see 4.2.5) and second the QIAamp viral mini spin procedure. 
The kit was used according to the manufacturer’s instructions 
The QIAamp viral step was conducted at KNMU (see 4.1.4).  
 
4.1.2.8 The Enzyme linked immunosorbent assay (ELISA) 
All sera samples were screened by ELISA using commercial ELISA kits (Vector best, 
Novosibirsk, Russia) for detecting antibodies IgG and IgM against CCHFV and 
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commercial kit for the detecting antibodies IgG and IgM against TBEV (Euroimmun, 
Germany) according to manufacturer’s instructions.  
According to the scheme of investigation, the paired sera that were screened for the 
presence of IgG and IgM antibodies against TBEV and CCHFV.  
In detail the first and the second sera was taken from the same patient in time 
differences 7-10 days. Firstly the second serum was screened for IgG. If the second 
serum of the paired human serum was positive for IgG, it was further investigated in the 
same run with first serum. In a case the first serum was negative for IgG, it was further 
investigated for IgM against TBEV and CCHFV. The first serum negative for IgM was 
accepted as immunity or old infection and vice versa positive for IgM was accepted as 
an acute phase of infection. In a case of two of paired sera were positive for IgG, they 
were titrated by two-fold. Further ELISA IgG of the first and the second sera against 
TBEV and CCHFV in the same run were made. The differences in four folds between 
the positive first and the second sera in the same run were considered as an acute 
phase infection and further investigated for the presence of IgM antibodies.  
In case the second serum was positive for IgM, the sera were investigated further by 
molecular methods of investigation.  
 
 
Figure 6.The scheme of sera investigation 
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4.1.2.9 TBE investigation with ELISA 
The paired sera were screened for the presence of antibodies IgG and IgM with 
ELISA. Antibodies against TBEV were detected by using the ELISA kit (Euroimmun AG, 
Germany). This test uses the TBEV viral proteins (strain K23) (www.euroimmun.com). 
Sera samples were diluted 1:100. The human antibodies attached to the viral TBE 
antigen on the plate. These antibodies were detected by peroxidase-labeled anti-human 
IgM or IgG. This complex visualized by chromogen substrate solution. The results were 
considered positive if it exceeded 1.1. The calculation was made according to the 
manufacturer instructions. The paired samples with OD difference <+0.3 were 
considered as IgG from the previous infection. But the samples with negative IgG of the 
first sera were tested for IgM. Due to the flaviviruses could have the cross-reactivity in 
ELISA detection (145). 
 
4.1.2.10 Immunofluorescence assay (IFA)  
 Kazakhstan is possibly endemic for other flaviviruses (6). Therefore sera samples 
tested positive in the ELISA have to be confirmed by other test systems. The 
immunofluorescence is widely used to detect the cross-reactivity with other flaviviruses 
(113). Herein, the positive IgG sera samples in ELISA were confirmed by the Flaviren-
Mosaik 1(IgG) (Euroimmun, Germany) IIFT according to manufacturerвЂ™s 
instructions. The IIFT Flaviren Mosaik 1 using the several Bioships coated with TBEV, 
WNV, JEV and YFV antigens, and the target samples could be tested simultaneously 
for other flaviviruses. The recommended dilution is 1:10. The positive samples were 
tested at dilution 1:10, 1:100, 1:200 and 1:300. All slides were investigated in a 
Microptix immune fluorescence microscope MF300 with 40x ocular. 
 
4.1.2.11 CCHF investigation with ELISA  
The all sera were investigated according to the scheme (See shown in annex xx). In 
a first step, 2nd sera of all participants were screened for IgG with ELISA (Vector-Best, 
Novosibirsk Russia) (dilution 1:100 as indicated by the kit instruction). Next, for the IgG-
positive subset, 2nd and 1st sera then were retested for IgG. Thus, first and second 
serum samples with OD difference <+0.3 were evaluated as an IgG resulting from a 
previous infection. Moreover, all other sera were titrated in log2-steps (1:100, 1:200 up 
to 1:3200). Four-fold titer change was assessed as acute infection. And at the third step, 
the samples whose 1st sera tested IgG-negative were than investigated by IgM ELISA. 
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Last, IgM negative and all IgM positive 1st sera these were further investigated by 
molecular methods (see 4.2.11). CCHFV RT-qPCRs and S and L segments PCRs 
The extracted RNA from the sera samples (see 4.8) were screened also for the 
presence of CCHF RNA (6). But the protocol was adapted 5 Вµl of CCHFV RNA was 
amplified in 25 Вµl RT-qPCR mixture QuantiTect Virus kit (Qiagen, Germany) with of 
0.2 ВµM of each primer, forward CCHF S1, reverse CCHFS122  and 0.16 ВµM of 
hybridization CCHF probe  with reagents according to the instructions and protocol as it 
was described before by Atkinson(106).  
 
Table 3. CCHFV Primers for RT-qPCRs (Atkinson et al. 2012) 
Primers/Probe Sequences 
S1, Forward primer TCT CAA AGA AAC ACG TGC C 
S2, Reverse primer CCT TTT TGA ACT CTT CAA ACC 
CCHF probe  FAM ACT CAA GGK AAC ACT GTG GCC 
GTA AG BHQ1 
 
The protocol was optimized on Rotorgen and Quiagen kit (Hilden, Germany).  
The amplified products of CCHFV RT-qPCR were run in agarose 1.5% with 100 bp 
marker and visualized by GelRed. The expected product size was 122 bp. Describe gel 
here to confirm positive samples.  
Samples positive for viral RNA in the RT-PCR were then analyzed by CCHFV 
specific RT-PCR with primers targeting the S segment forward primer CCHF RWCF ) 
and reverse primer CCHF RWCR(130) and L segments  
 
Table 4. CCHFV primers for conventional S and L segments PCR 
Segment Forward Reverse 
S 
segment  
RWCF 
CAAGGGGTACCAAGAAAATGAAGAAGGC 
RWCR 
GCCACAGGGATTGTTCCAAAGCAGAC 
L 
segment  
F2576 
5’-gggAAAATAAggACAgACCA 
R3371 
5’-TCYgTTAAgCATTCATTRCT 
 
The amplified products were run in agarose 1.5% gel and visualized by Gel Red® 
under illumination of ultraviolet light. 
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4.1.2.12 Sequencing  
Products of conventional PCR were purified with Qiaquick PCR purification kit 
(Qiagen, Germany) according to the manufacturer’s instruction with the ABI Prism Big 
Dye Terminator V3.1 Cycle Sequencing Kit and “3500xl Genetic Analyzer” machine 
using the initial primers of RT-PCR amplification. Retrieved sequences were xxxxx 
Phylogenetic trees were constructed in MEGA 6 with the Maximum Likelihood method 
based on the Tamura 3-parameter model (131)(132)(133) 
 
4.1.2.13  Data analyzing and statistics  
Hypotheses 
We wish to investigate whether the prevalence of CCHF and TBE in Almaty Oblast is 
above the threshold for the designation of the region as endemic and patients with FUO 
should be routinely tested for the infection. While the prevalence threshold for a region 
to be designated as endemic is not officially stated, we take five percent as a 
reasonable criterion. As, the expected prevalence of TBE should not exceed 5%. We 
suggested that the calculated sample size will be reasonable for TBE investigation also. 
Thus, a prevalence level below five percent would be considered as non-endemic and 
anything above as endemic. Our hypotheses can be stated as follows:  
H0: The prevalence of CCHF infection in Almaty Oblast is 5%, or less. 
H1: The prevalence of CCHF infection in Almaty Oblast above 5%. 
   Power calculation and the sample size 
We wish to collect a sample that would allow us to detect a potential prevalence of 
two percent above this threshold or more. Thus, if the true prevalence in Almaty Oblast 
was seven percent of more, we want to have enough data to allow us to reject H0. The 
power calculation is for one-sided z-test with five percent probability of false positive 
(Type I error(134)(135), i.e. p-value < 0.05 required for rejecting H0, is 
0.07 − 0.05
𝜎
√𝑛
> 1.645 
 
where the standard deviation of CCHF prevalence under H0 is at most 
𝜎 = √(0.05(1 − 0.05)) = 0.218. 
Plugging this into the inequality above and solving for the sample size, we obtain 
𝑛 > (1.645
0.218
0.02
)
2
= 321.5. 
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Thus, the appropriate sample size for testing H0 is 322 or more. 
Methods of statistical analyzing of the CCHF and TBE seroepidemiological 
study  
The proportion of seropositive patients’ calculation and the statistical analyzes to 
evaluate the independent risk factors for seropositivity were made for both infections. 
Statistical analyses were conducted by using R 3.3.324. Logistic regressions were used 
to evaluate the independent risk factors for seropositivity. The criterion for statistical 
significance was p < 0.05. Questionnaire responses from CCHFV and TBEV positive 
patients were compared with those from CCHFV and TBEV infection negative 
participants.  
Methods of statistical analyzing of results of tick’s investigation study  
 The prevalence of TBEV and CCHFV in ticks was calculated as a minimum infection 
rate (MIR) assuming that one tick in each pool was definite as a positive. Due to the 
studied arboviruses have a low prevalence not exceed 5% in investigated pilot regions, 
the best approach to calculate the prevalence is MIR(136). It is explained that 
confidence interval of the MIR based on Poisson distribution and it is appropriate if the0 
infection level is low. Due to the MIR based on Poisson distribution, the results of the 
MIR are sensitive for the prevalence of infection, it should not be that only one positive 
individual is in a total sample size or the prevalence of infection is high. In a case of high 
prevalence or in a case of only positive individual in total sample, the result of MIR 
calculation will be invalid and biased(137).  
During the project study, the MIR was established by the sampling sites and tick 
species. 
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5 CHAPTER 5 
5.1 Results 
5.1.1 Ticks investigation study. 
5.1.1.1 The Ticks investigation  
In this study we investigated TBEV in ticks from endemic and non-endemic oblasts in 
Kazakhstan to obtain the information on the prevalence of TBEV in vectors and 
circulating subtypes. 
Overall, 2341 ticks or 501 pools of ticks were investigated from six regions of Almaty 
oblast and Kyzylorda. In general, collected ticks were determined as five genera Ixodes, 
Dermacentor, Haemophisalis, Ripecephalus and Hyaloma. Thoroughly, Ixodes 
persulcatus (1191 imagoes and two nymphs), Dermacentor marginatus (55 imagoes), 
Haemophisalis punctata (470 imagoes), Dermacentor reticulatus (14 imagoes), 
Dermacentor niveus (523 imagoes), Ripecephalus turanicus (9 imagoes), Hyaloma 
asiaticum (77 imagoes).  
In detail In Almaty oblast 1737 ticks were collected or 365 pools. In Tekeli district 
were collected I. persulcatus 610 ticks or 123 pools, H. punctata 25 ticks or 7 pools, D. 
marginatus 50 ticks or 12 pools, D. niveus 10 ticks or three pools, D.reticulatus 14 ticks 
or three pools. In Yenbekshikazakh district were collected I. persulcatus 79 ticks or 16 
and one pool of I. persulcatus nimphae pools, H. punctata 444 ticks or 96 pools. In 
Talgar district of Almaty oblast were collected I. persulcatus 50 ticks or 103 pools H. 
punctata nimphae and one pool respectively (see table 5).  
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 Table 5. The ticks collected in Almaty oblast 
 
In Kyzylorda oblast ticks were collected in three districts Zhanakorgan district, Shiely 
district and Syrdariya districts at 18 sites, respectively. 604 ticks or 136 pools were 
collected in Kyzylorda oblast. In Zhanakorgan district were collected D. niveus 116 ticks 
or 25 pools, H. asiaticum 77 ticks or 17 pools, R. turanicus were collected 6 ticks or two 
pools. In Shiely district were collected D.niveus 119 ticks or 43 pools, R. turanicus three 
ticks and three pools as the ticks were different gender or site of collection. In Syrdariya 
district were collected D. marginatus five ticks or three pools and D. niveus 198 ticks or 
43 pools (see table 6).  
 
Table 6. Ticks species collected in Kyzylorda oblast 
Regions  Tick species Ticks/pools 
Zhanakorgan  D. niveus (Imago) 116 ticks /25 pools 
Hyalomma asiaticum (Imago) 77 ticks/ 17 pools 
Ripicephalus (R ) turanicus 6 ticks/ 2 pools 
Shiely D. niveus (Imago) 119 ticks / 43 pools 
R. turanicus (Imago) 3 ticks/3 pools (different 
gender and site of collection) 
Syrdariya D. marginatus (Imago) 5 ticks/3pools 
D. niveus (Imago) 198 ticks/ 43 pools 
 
Regions  Tick species Ticks/pools 
Tekeli Ixodes (I) persulcatus (Imago)  610 ticks/ 123 pools 
Haemophisalis (H) punctata 
(Imago) 
25 ticks/ 7 pools 
Dermacentor (D) marginatus 
(Imago) 
50 ticks/ 12 pools 
D. niveus (Imago) 10 ticks /3 pools 
D. reticulatus (Imago) 14 ticks/ 3 pools 
Yenbekshikazakh I. persulcatus (Imago) 78 ticks /16 pools 
I. persulcatus (Nimphae) 1 nimphae/ 1 pool 
H. punctata (Imago) 444 ticks /96 pools 
Talgar I. persulcatus (Imago) 504 ticks /103 pools 
H. punctata 1 nimphae / 1pool 
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The 18 GPS coordinates of the sites of tick collection locations are shown in a map in 
figure 5. I.persulcatus was only found in Almaty oblast in Talgar region next to the 
mountains. H. punctata were mostly collected in region with meadows in 
Yenbekshikazakh region. whereas D. niveus and H. asiaticum tick were only detected in 
Kyzylorda oblast. D. niveus were in all three regions of Kyzylorda oblast but not far from 
the water source the river Syrdariya, whereas H.asiaticum was collected only in 
Zhanakorgan far from the source of water (See the pilot regions in Introduction). Hence, 
I. persulcatus was prevailed in Almaty oblast and D. niveus and H. asiaticum were 
prevailed in Kyzylorda oblast 
 
5.1.1.2 Investigation of TBEV in ticks  
TBEV RNA only was found in ticks collected in Almaty oblast while in Kyzylorda 
oblast no positive tick pools were found. In detail 51 positive pools (14%) were detected 
in Almaty oblast. 22 positive pools (6.%) for TBEV RNA positive pools were detected in 
Talgar region, 22 positive pools (6%) were detected in Tekeli region and only seven 
(2%) were detected in Yenbekshikazakh region. The Minimum Infection Rate (MIR) of 
ticks from Almaty oblast (Tekeli, Yenbekshikazakh, Talgar regions) was calculated. The 
MIR displayed in geographically appearance of TBEV are Tekeli (3.1%), 
Yenbekshikazakh (1.3%) and Talgar (4.4%) respectivelly. Moreover the MIR divided in 
different ticks genus are I. persulcatus (15.4%), H. punctata(0.2%), and D. marginatus 
(2%). Results are shown in a table (see table 7). 
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Table 7. MIR% by tick species and regions in Almaty oblast, Kazakhstan 
 
In summary 51 TBEV positive samples were further investigated by TBEV specific 
conventional RT PCR with primers targeting the complete E gene and all positive 
samples were subsequently sequenced. In detail, in Talgar region 22 pools were 
Oblast Region Number 
of 
ticks/pool 
size 
Tick species/ 
number of pools 
Number 
of 
positive(po
ols in real 
time PCR 
by gender 
MIR
% by 
tick 
species 
MIR% 
by 
regions 
 
 
 
 
 
 
 
 
 
 
 
Almaty 
oblast 
Talgar 
  
505/104 I. persulcatus 
504/103 
 
♂ 7/49 
 
 
4.4% 
4.4% 
♀ 15/53 
Nymphs 
0/1 
H. punctata 1/1 ♂ 0/0  
0% ♀ 0/1 
Tekeli  
 
 
709/148 D. marginatus 
50/12 
 
 
♂ 0/3 
♀ 1/9  
 
 
2% 
3.1 % 
D. reticulatus 14/3 
 
♂ 0/1   
0% ♀ 0/2  
I. persulcatus 
610/123 
 
♂ 4/54  
3.4% ♀ 17/69 
 
H. punctata 25/7 ♂ 0/4   
0% ♀ 0/3  
  D. niveus 10/3 ♂ 0/3 0%  
Yenbekshikazakh  523/113 I. persulcatus 
79/17 
♂ 3/7   
7.6% 
1.3% 
♀ 3/9 
Nymphs 
0/1 
H. punctata 
444/96 
♂ 1/43 
♀ 0/53 
 
0.2% 
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positive for the TBEV RNA presence. But only 14 were positive in E target conventional 
PCR with primers forward 947 A +947 B and reverse 2579 (primer details see in table 
8). In Tekeli region, the 22 positive pools for the presence of TBEV RNA were positive 
in qRT-PCR and only 19 in target E gene conventional PCR with primers forward 947 
A+947 B and reverse 2579 only 19 pools were positive (see table 8). 
In comparison to Tekeli and Talgar regions, in Yenbekshikazah seven positive pools 
the presence of TBEV RNA was detected in real time RT-PCR. But only 5 positive pools 
were positive for target E gene with primers forward 885 and reverse 2579. However, 
one pool was also positive with primer combination forward 885 and reverse 2605. (see 
table 9) 
All amplificates of the E.gene had a size of 1687 nt. 
 
Table 8. The positive pools from Talgar and Tekeli regions for target E gene PCR 
Region  Tick species The 
gender of 
positive 
ticks  
Number 
of positive 
pools/ CT  
Target E gene PCR  
Primers 
Forward 947 A+947 B 
Reverse 2579 
 
Sequenced  
Talgar  I.persulcatus  ♀15 22 /CT 
bellow 39 
14 11 
♂7 
Tekeli  I.persulcatus ♀17 22/CT 
bellow 39 
19  15 
♂4 
D.marginatus ♀ 2    
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Table 9. The positive pools from Yenbekshikazakh region for target E gene RT-PCR 
 
 
Hence during the sequencing of E gene the 1488 nt open reading frame, 11 
sequences of E gene from Talgar region, 15 sequences from Tekeli region (see table 8) 
and four sequences from Yenbekshikazakh were detected ( see table 10).  
 
Table 10. The sequences of E gene of 30 samples and GenBank accession number  
No 
 
 
 
 
Year Gender Host Region GenBank 
accession number 
17 2015 ♀ I. persulcatus Talgar MK284381 
21 2015 ♂ I. persulcatus Talgar MK284382 
25 2015 ♀ I. persulcatus Talgar MK284383 
44 2015 ♂ I. persulcatus Talgar MK284384 
45 2015 ♀ I. persulcatus Talgar MK284385 
49 2015 ♀ I. persulcatus Talgar MK284386 
50 2015 ♀ I. persulcatus Talgar MK284387 
54 2015 ♂ I. persulcatus Talgar MK284388 
64 2015 ♀ I. persulcatus Talgar MK284389 
66 2015 ♂ I. persulcatus Talgar MK284390 
68 2015 ♂ I. persulcatus Talgar MK284391 
5 2015 ♀ I. persulcatus Tekeli MK284392 
28 2015 ♀ I. persulcatus Tekeli MK284393 
33 2015 ♀ I. persulcatus Tekeli MK284394 
53 2015 ♀ I persulcatus Tekeli MK284395 
58 2015 ♀ I. persulcatus Tekeli MK284396 
Region Tick species The 
gender 
of 
positiv
e ticks  
Number 
of positive 
pools  
Target E gene PCR 
 885 forward and 2579 
reverse 
885 forward and 2606 
reverse 
Sequen
ced 
Yenbekshik
azakh  
I. persulcatus  ♀3 7 5 4 
♂3 
H. punctata  ♀1 
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61 2015 ♀ I. persulcatus Tekeli MK284397 
99 2015 ♀ I. persulcatus Tekeli MK284398 
101 2015 ♀ I. persulcatus Tekeli MK284399 
105 2015 ♂ I. persulcatus Tekeli MK284400 
111 2015 ♀ I. persulcatus Tekeli MK284401 
113 2015 ♀ I. persulcatus Tekeli MK284402 
118 2015 ♀ I. persulcatus Tekeli MK284403 
120 2015 ♂ I. persulcatus Tekeli MK284404 
133 2015 ♀ I. persulcatus Tekeli MK284405 
137 2015 ♀ I. persulcatus Tekeli MK284406 
75 2015 ♀ I. persulcatus Yenbekshikazakh MK284407 
77 2015 ♂ I. persulcatus Yenbekshikazakh MK284408 
109 2015 ♀ H. punctata Yenbekshikazakh MK284409 
112 2015 ♂ I. persulcatus Yenbekshikazakh MK284410 
  
30 sequences classified our sequences as Siberian subtype of TBEV on nt and aa 
level. Strain Zausaev was used as a reference strain (see table 10). The Talgar and 
Yenbekshikazakh sequences are belong to Baltic lineage of Siberian subtype, whereas 
Tekeli sequences belong to Vasilchenko lineage of Siberian subtype(18). In detail, the 
sequencing of the 1488nt E-gene open-reading frame leads to 30 E-gene sequences. 
11 sequences from Talgar region, four sequences from Yenbekshikazakh region and 15 
sequences from Tekeli region of Almaty oblast (see table 11).  
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Table 11. Amino acid substitutions in the E-protein with the reference strain Zausaev 
Strain/aa-pos. 33 41 52 83 88 93 128 150 228 233 277 279 310 313 331 342 384 387 395 430 431 435 460 475 482 487 490 494 
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Comparison of the Talgar E-gene sequences with GenBank entries (Stephen F et al, 
1997) revealed highest similarities on the nucleotide level (94-95 %, 81-83 nt difference) 
to the sequence of the strain Buzuuchuk (KJ626343) and on the amino acid (aa) level 
with the strain MucAr M14/10 (AFU65175) (99 %, 6 aa difference). Comparison of the 
Yenbekshikazakh E-gene sequences with GenBank entries revealed highest similarities 
on the nucleotide level (94 %, 84nt difference) to the sequence of the strain Buzuuchuk 
(KJ626343) and on the amino acid (aa) level with the strain MucAr M14/10 (AFU65175) 
(99 %, 6 aa difference). Phylogenetic analyses show that both, strains from Talgar and 
from Yenbekshikazakh are clustering in the Baltic lineage of the Siberian Subtype (see 
figure 7a). Comparison of the Tekeli E-gene sequences with GenBank entries revealed 
highest similarities on both, the nucleotide level (99%, 15-21 nt difference) and the 
amino acid (aa) level (99%, 1-2 aa), to the sequence of Sib-XJ-X5, clustering in the 
Siberian Subtype (Vasilchenko lineage) (see figure 7a). Phylogenetic analyses of the 
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496 aa show that all three strains are clustering together in one clade with the strain 
Sib-XJ-X5 (see figure 7b).  
 
 
Figure 7. Phylogenic analysis of E-gene of TBEV. Phylogenetic tree illustrating the evolutionary 
relationships of nucleotide (nt) and amino acid (aa) taxa. The trees were constructed with the MEGA7 
software package using the Neighbor-Joining method (Saitou et al.1987, Kumar et al. 2016). The 
percentage of replicate trees are shown next to the branches, bootstrap test was made in 10.000 
replicates (Felsenstein et al. 1085). Omsk hemorrhagic fever virus (AF482341) applied as an outgroup. 
The newly acquired Kazakh sequences are marked with squares (Tekeli), circles (Talgar) and triangles 
(Yenbekshikazakh). The former published TBEV sequences from Kazakhstan are marked with diamonds. 
a) Phylogenetic tree of the open-reading from of the E-gene using 70 nucleotide sequences with the 
length of 1488nt 
 
5.1.1.3 Investigation of CCHFV in ticks. 
All RNAs from ticks were also investigated for the presence of CCHFV RNA by real-
time RT-PCR. No positive tick pools the presence of CCHFV RNA were found. All 
positive controls and negative controls worked. 
 
5.1.2 Seroepidemiological investigation of TBE and CCHF in patients with 
FUO 
5.1.2.1 Enrolled patients  
In total, 950 patients were enrolled from 13 hospitals in the two oblasts Almaty and 
Kyzylorda into the study. However, for 148 patients either only one serum, no 
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questionnaire or no consent form was available. Therefore only 802 patients with a 
fever of unknown origin were meeting the criteria, to have paired serum pairs as well as 
the questionnaire, and were therefore used for the study.  
 
5.1.2.2 TBEV serological investigation by TBEV IgM and IgG ELISAs 
According to TBE investigation, it was revealed that the total seroprevalence of TBE 
infection in Almaty oblast and Kyzylorda oblast was 16 out of 802 (1.9%) and two out 
802 (0.25 %) respectively. In the screening for IgM for the acute TBE infection six 
samples (0.74%) out 802 and two samples (0.25%) out 802 were detected in Almaty 
and Kyzylorda oblast respectively. In terms of IgG, ten samples (1.24%) were revealed 
in Almaty oblast and no IgG positive samples in Kyzylorda oblast. 
 
5.1.2.3 Confirmation of results by the Immunofluorescence (IFAT) 
According to the immunofluorescence confirmation often TBEV IgG positive samples 
was indicated that all TBE IgG positive samples are TBEV as in the dilution row only a 
reaction with TBEV antigen stayed. The light was evaluated between weak and strong 
with a dilution 1: 10.The positive control for TBEV IgG and for positive control anti-
Japanese Encephalitis virus were positive (see table 12).  
 
5.1.2.4 Statistical analysis of seroepidemiological TBEV investigation 
The evaluation of clinical symptoms was revealed that patients had symptoms as 
headache fever (n= 18, 100%), headache (n=17, 94.4%), weakness (n=10, 56%), 
meningism (n= 5, 28%), exanthema (n=2, 11.1%), diarrhea (n=1, 5.5%). It was also 
revealed that only two patients out eight with acute TBEV had meningeal symptoms: 
These were not treated as TBE patients or diagnosed at the hospital according to 
clinical signs with this infection. All patients with acute TBEV infection had ever higher 
than 37.5 and lasting more than four days. With regards to the risk factors, we have 
found that ticks bite in history and living surroundings as occasional bush agricultural 
fields increase the TBE seropositivity (p<0.05). However, the history of contact with any 
animals and birds, the area of living urban or rural do not affect the seropositivity. The 
analysis of socio-demographic aspects of the TBEV seropositive proportion of patients 
shows gender equality among seropositive patients. The mean age of seropositive 
patients was 32 years old. The analysis of seropositive patients by their occupation 
revealed that the unemployed were (n=8, 44.4%), students were (n=4, 22%) and skilled 
laborers were only (n=3, 16.6%) 
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Table 12. Confirmation of TBEV ELISA results by flavivirus IFAT 
Sample number/age/ 
Gender ( 
Titers in ELISA IgG 
(Euroimmun, Germany) 
 IFA (Euroimmun, Germany) 
Almaty 55, 20, f 1:101 1st TBEV 1:300 
2nd TBEV 1:300 
Almaty 45, 27, m  1:101 2nd TBEV 1:300 
1st TBEV 1:300 
Almaty 10, 24, m 1:101  2nd TBEV 1:10 
1st TBEV 1:10 
Taldykorgan,30, 45, m 1:101  1st TBEV 1:300 
2nd TBEV 1:300 
Tekeli 13, 64, m 1:101 1st TBEV 1:100 
2nd TBEV 1:100 
Tekeli 15, 60, f 1:101 1st TBEV 1:300 
2nd TBEV 1:300 
Tekeli 31, 25, m 1:101 2nd TBEV 1:100 
1st TBEV 1:100 
Tekeli 38, 19, f 1:101 2nd TBEV 1:200 
1st TBEV 1:200 
Tekeli 40, 18, f 1:101 2nd TBEV 1:100 
1st TBEV 1:100 
Tekeli 64, 51,f 1:101 2nd TBEV 1:100 
1st TBEV 1:100 
 
5.1.2.5 CCHF ELISA results 
The paired sera of 802 samples were screened for the presence of IgG against 
CCHFV antibodies. 
In summary, 378 patients (47.1%) originated from Almaty oblast (not endemic for 
CCHF oblast) and 424 patients (52.9%) from Kyzylorda oblast (endemic for CCHF 
oblast). The first screening of second sera revealed 50 samples positive for IgG against 
CCHF in Almaty oblast and 70 samples in Kyzylorda oblast. In detail, during the first 
screening into the account, positive and all equivocal samples were taken into account 
with OD >1 as positive and 0.8-1 equivocal. In a second step for all samples reacting 
win the CCHFV IgG ELISA a simultaneous screening for the presence of IgG in the first 
and second sera was performed. The second step revealed that only 62 out 70 (88.5%) 
samples from Kyzylorda were positive for IgG in both sera and only 44 out of 50 (88%) 
samples originating from patients from Almaty oblast were positive for CCHFV IgG in 
both sera. Hence, during the second screening, almost 12 equivocal samples from 
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Kyzylorda oblast and six equivocal samples from Almaty oblast were negative in the first 
and second sera. These samples were skipped from further investigation. However, 
three samples from Kyzylorda oblast were CCHFV IgG negative in first sera and 
positive in second serum. The following titration of CCHFV IgG-seropositive samples 
revealed any differences in both samples of 58 samples from Kyzylorda oblast and 44 
samples from Almaty oblast. However, in four samples from Kyzylorda oblast, a four-
fold difference in TBEV IgG titers was revealed. These samples were further tested for 
the presence of IgM. IgM antibodies were detected in the second sera of three samples 
(Kyzylorda 43, Kyzylorda 121, Shiely 26) and one sample (Syrdariya 6) was positive for 
IgM in both sera (see table 13). 
 
Table 13. The results of sera investigation for the presence IgG and IgM antibodies 
against CCHFV by ELISA 
Oblast  Region The first 
screening of 
second sera 
for IgG 
 
The 
second 
sreening of 
first and 
second sera/  
Titration  
Four 
fold 
differences 
IgM 
First 
serum 
IgM  
Second 
serum 
Kyzylorda  Kyzylorda  28 25 2 0 2 
Zhanakorgan  13 13 0 0 0 
Shiely 15 15 1 0 1 
Syrdariya  14 9 1 1 1 
Almaty Almaty 28 28 0 0 0 
 Kaskelen  2 0 0 0 0 
 Usharal  4 4 0 0 0 
 Taldykorgan  7 7 0 0 0 
 Kabanbay 1 1 0 0 0 
 Tekeli  6 4 0 0 0 
 
Hence, only in three samples (two samples from Kyzylorda and one sample from 
Shiely) the IgG were equivocal in the second sera but negative in the first, were positive 
for IgM antibodies against CCHFV in the second sera. These samples were not 
included in the group of IgG positive samples. Moreover, in the first sera of these 
samples, CCHFV RNA was detected. Hence all positive serum samples with a four-fold 
difference in a titration of CCHFV IgG or equivocal in the second for CCHFV IgG 
antibodies and negative in the first serum for IgG antibodies were screened for CCHFV 
IgM according to the scheme sera investigation ( See 4.2.8). According to this scheme,  
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one more positive sample for IgM antibodies against CCHFV was detected in Syrdariya. 
Therefore, from all serum samples included in the screening for acute infections using 
IgM ELISA four samples (0.5%) were positive for IgM antibodies. Three of these 
samples (0.4%) from patients with FUO were also positive for CCHFV RNA (See table 
14). 
 
Table 14. The results of CCHFV ELISA and RT-PCR in patients with FUO investigated 
in two oblasts in Kazakhatsn (2014-2015) 
 
 
5.1.2.6 Acute infection of CCHF 
During the screening of all positive sera for IgM antibodies against the CCHFV, it was 
revealed that four sera samples were positive for IgM antibodies against CCHFV. The 
second sera of three samples were positive for IgM (Kyzylorda 43, Kyzylorda 121 and 
Shiely 26). These three samples are unique as CCHFV RNA was detected in the first 
sera.  Also, one serum was positive for IgM (Syrdariya 6) but the first serum. Among 
these four positive samples, three patients (Kyzylorda 121, Shyeli 26 and Syrdariya 6) 
had the subclinical manifestation of CCHF. 
Only one patient positive for IgM against CCHF (Kyzylorda 43) developed the CCHF 
with specific clinical manifestation as a hemorrhagic syndrome. In detail, the patient was 
a woman born in 1993, developing the disease five days after a tick bite. The tick bite 
was on the left shoulder on 20.07.2015, and on the same day, the tick was removed by 
the patient. The disease onset was on 25.07.2015 with high temperature, heavy, and 
muscle pain. The patient took Acetaminophen (Paracetamol). Due to the health 
deterioration, she went to the village hospital, and she was sent to the regional 
  Oblast Almaty Kyzylorda Sum 
Number of all tested samples 378 (47.1%) 424 (52.9%) 802 
Number of seronegative samples  334/802 
(41.6%) 
362/802 
(45.1%) 
696 (86.8%) 
Number of IgG sepositive samples  44/802 (5.5%) 58/802 (7.2%) 102/802 
(12.7%)  
Number of IgM 
positive samples 
1st serum 0/802 (0%) 1/802 (0.1%) 4 (0.5 %) 
2nd serum 0/802 (0%) 3/802 (0.4%) 
Prevalence of seropositive samples 
by oblasts  
44/378 
(11.6%) 
62/424 
(14.6%) 
106/802(13.2%) 
Number of RT-qPCR positive 
samples (%) 
0/802 (0%) 3/802 (0.4%) 3/802 (0.4%) 
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infectious disease hospital with clinical diagnosis Rickettsiosis.  Only at the regional 
infection disease hospital, the patient was hospitalized to the intensive care department 
with diagnosis "Crimean-Congo hemorrhagic fever" as during the examination the signs 
of the hemorrhagic syndrome were revealed. The appearance of the hemorrhagic 
syndrome was presented as hematomas and nasal bleeding. On the day of admission 
in the blood analysis was revealed thrombocytopenia. The blood analysis on the day of 
admission 27.07.2015, (19-35 PM) - Thrombocytes - 230- 10*9 / L (Norm- 180-320), 
Leukocytes -4.4 - 109 / l, ESR (Erythrocytes sedimentation rate)-13 mm / h, RBC (red 
blood cells) 4.5, Hemoglobin-120 g / l. The level of thrombocytes decreased and 
reached on the fifth day of the disease 30.07.2015 Blood - thrombocyte-38- 10*9 / l, 
Leukocytes -1.9 – 10*9 / l, ESR-26mm / h, RBC-3.9, Hemoglobin -118 g /l. The level of 
liver enzymes was within the norm. The diagnosis was proved with CCHFV-specific 
ELISA and RT-PCR. 
In three samples CCHF RNA was revealed. The S and L segments were 
characterized with sequence analyzing. The phylogenic analysis was performed 
(4.3.1.2). The studied sequences were aligned with reference sequences of S (180 nt) 
and L (220 nt) segments. According to S segments the CCHFV groups into seven 
clades according to the geographical distribution (1.West –Africa, 2. Central Africa, 
3.South Africa, and West-Africa, 4.Middle East and Asia, 4.Asia 1, 5.Asia 2, 6.Europe 
Clade, 7.Greece). According to L segment the CCHFV topology the same as with S 
segment(138). Hence the analysis of the partial S and L segments of three samples 
(Kyzylorda 43 (Kyz 43), Kyzylorda 121 (Kyz 121), Shiely 26 (Sh 26) were conducted. 
The gene bank accession of S segments Kyz43 MG974100, Kyz121 MG974101, Sh26 
MG974102 and of L segments Sh26 MG974103, Kyz43 MG974104. In the analysis of 
the partial S Segment, all three detected CCHFV RNAs from Kazakhstan clustered in 
subgroup Asia 2 (see figure 8). Analysis of partial L segments of the sample Kyzylorda 
43 revealed a clustering in subgroup Asia 2 with strains from Tadjikistan (AY20893, 
KX013444) and a strain from 1971 from Kazakhstan (KX01354453). However, the 
partial L segment from sample Shiely 26 clustered in subgroup Asia 1 with strains from 
Iraq, Afghanistan, and India. Therefore, for the sample Shiely 26, recombination 
between the two Asian subtypes of CCHFV is present (see figures 9). 
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Figure 8. Phylogenic analysis of the partial Small (S) gene fragment of CCHFV. 
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Figure 9. Phylogenic analysis of the partial Large (L) gene fragment of CCHFV 
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5.1.2.7 Statistical analysis of seroepidemiological CCHF investigation  
Despite the clinical appearance of seropositive patients, the questionnaires showed 
that patients had only not specific and mild symptoms such as headache (n= 99, 
93.4%), fever (n= 104, 98.1 %), weakness (n= 81, 76.4 %), exanthema (n= 33, 31.1%), 
and diarrhea (n= 13, 12.3%).  
The proportion of seropositive patients' calculation and the statistical analyses to 
evaluate the independent risk factors for seropositivity were made for both infections. 
Statistical analyses were conducted using R 3.3.324. Univariate logistic regressions, 
reported in table 1, did not identify a statistically significant difference in the prevalence 
of seropositivity between males and females. Seropositivity is also unrelated to age. 
Urban areas tend to have lower seropositivity than rural areas; however, this result is 
only statistically significant at the 10% level. 
Concerning the risk factors, we have found that animal husbandry increases the 
prevalence of seropositivity (p < 0.05). However, history of tick bites or presence of 
birds does not affect seropositivity. It has obtained similar results using univariate OLS 
regressions with robust standard errors. Finally, breaking down the animal husbandry, 
we have found that, with the exception of pigs, higher frequency of contact with all other 
animals for which we have collected data (sheep, goats, cattle, horses, cats, and 
poultry) leads to an increased prevalence of seropositivity, however, the effects are only 
statistically significant for cattle and horses. The univariate logistic regression identified 
that the seropositivity significantly unrelated to the patient's occupation as students, 
farmers, housekeeper, driver, unskilled labor, administrative workers, workers of a 
medical facility, people in business, farm workers who work with plants. However, the 
univariate logistic regression detected statistically significant relation only between 
seropositivity and farmers who work with animals p<0.05 (see table 15) 
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Table 15. Characteristics of CCHFV seropositivity in patients with FUO in Kazakhstan 
(2014 – 2015)* 
 
Variables 
Seronegative 
IgG (n = 696) 
Seropositive 
(n = 106) 
Univariate logistic regressions 
explaining seropositivity  
Logistic  
(change in OR) 
OLS  
(change 
in 
probability) 
Gender:    
-0.071 
(p> 0.05) 
-0.008 
(p> 
0.05) 
Male 427 64  
Female 261 42  
NA 8 0 
Age:   
0.005 
(p> 0.05) 
0.001 
(p> 
0.05) 
Mean 35 35 
Standard deviation 16 15 
History of tick bites:    
-0.253 
(p >0.05) 
-0.028 
(p 
>0.05) 
Yes 159 20  
No 531 86  
NA 6 0 
Animal husbandry:   
0.508 
(p <0.05) 
0.059 
(p 
<0.05) 
Yes 290 48 
No 399 58  
NA 7 0 
Birds or nests at home:   
0.061 
(p >0.05) 
0.008 
(p 
>0.05) 
Yes 97 19 
No 399 97  
NA/does not know 409 0 
House location:   
-0.364 
(p> 0.05) 
-0.042 
(p> 
0.05) 
Rural area 328 60 
Urban area 362 46  
NA 6 0 
Occupation  
  
 
 
Student/Pupil   97        
    17       0.446 
p>0.05 
   0.048 
p>0.05 
Farmeworker  
 
 
      
Plants   11 
   
     2 
     0.495 
     (p>0.05)  
 
  0.186 
 
(p<0.05) 
Animals   10 
 
4 
    1.283  
    (p<0.05) 
0.186 
  
(p<0.05) 
Forestry  8 
     
     1 
0.063 
    (p>0.05) 
0.006 
  
(p>0.05) 
Housekeeper 27 
 
     6 
     0.665 
(p>0.05) 
 
0.079 
(p>0.05) 
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Unskilled Labourer 40 
8      0.579 
(p>0.05) 
0.066 
(p>0.05) 
Driver 20 
5      0.813 
(p>0.05) 
0.100 
(p>0.05) 
Administraion/Academic 
professional 
55 
8 0.264 
(p>0.05) 
0.027 
(p>0.5) 
Business man/woman 17 
2 0.005 
(p>0.05) 
0.0009 
p>0.05 
Nurse/Physician/Pharmacist 19 
1 -1.089 
p>0.05 
-0.085 
 p>0.05 
Other profession 124 
14      0.013 
p>0.05 
0.001 
p>0.05 
Unemployed 137 
24 0.443 
p>0.05 
 0.048 
p>0.05 
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6 CHAPTER 6 
6.1 Discussion 
6.1.1  Investigation of TBEV in ticks  
One of the primary aims of this thesis was the investigation of TBEV and CCHFV in 
vectors.  
The first aim was to investigate TBEV in ticks; in detail, to estimate the prevalence in 
ticks, a circulating subtype and to describe the TBEV vectors. 
Hence, in Kyzylorda, four species of ticks were detected D. niveus, D. marginatus, R. 
turanicus and H. asiaticum. Our findings are consistent with previous studies on ticks 
performed in Kazakhstan. In these studies, seven species of ticks were described in 
Kyzylorda as D. niveus, D. marginatus, R. turanicus, H. asiaticum, H. punctata, 
Hyalomma suspense, Rhicephalus pumilio (36). Our study demonstrated that tick 
species D. niveus (111 pools) was dominant among other species D. marginatus (3 
pools♀), H. asiaticum (13 pools♂ and 4 pools ♀), R. turanicus (3pools♂, 4 pools ♀). 
Following our data, tick species D. niveus (111 pools) is dominant in this region. It could 
be explained that the prevalence of tick species is affected by the peak of activity, time 
of tick sampling and geographical distribution of ticks D. niveus. D. niveus inhabit mostly 
the flood plains as they need the optimal level of humidity for the living and oviposit and 
altitude not more 1500 meters above the Sea (139). The structure of Haller' organ could 
explain the geographical inhabiting of flood plains by D. niveus. In contrast to H. 
asiaticum, Haller's organ of D. niveus has not mature glands that could provide the 
constant level of moisture continent (140). Also, the tick sampling was conducted at the 
pick activity of D. niveus. The pick of activity of D. niveus in Kazakhstan is in April, 
March, and May. During these months, the temperature on average is mild. Moreover, 
the weather is still humid this time of year  (141). The tick sampling was conducted in 
Kyzylorda oblast in an area of Syrdariya river flood plain that has favorable conditions 
for D. niveus. In contrast to D. niveus the activity of D. marginatus (5 pools), R. 
turanicus (3 pools) appeared later. Moreover, D. marginatus inhabit mostly steppes and 
semi steppe regions, and inhabiting does not require only the flood plains and can 
range until 3000 meters above the sea (142). Our findings on H. asiaticum (17 pools) 
reflect the time of tick activity and results of previous published studies conducted in this 
region. The tick activity of H. asiaticum in this area starts later and last till the end of 
July, as this species more adaptive for dry and hot weather because of the structure of 
cuticle and Haller’s organ, the glands of Haller’s organs providing good moisturizing 
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(142). 64 pools from Almaty oblast were investigated and five tick species I. persulcatus 
(131 pools♀, 110 pools♂, 2 pools nymphs), H. punctata (110 pools ♀, 47 pools ♂), 
D.niveus (3 pools♂), D. marginatus (9 pools ♀, 3 pools♂), D. reticulatus (2 pools♀, 1 
pool ♂) were found. The observation over the ticks in our study revealed that the tick 
species I. persulcatus (242 pools), H. punctata (104 pools) have prevailed in contrast to 
other tick species collected in Almaty oblast. According to the previous published tick 
studies , I. persulcatus and H. punctata are endemic in Almaty region as they prefer 
humidity and can inhabit the territories with an altitude up to 2000 meters above the sea 
level (140). Almaty oblast was shown to have a favorable condition for the appearance 
of the ticks of the species I. persulcatus and H. punctata (8). The distribution of ticks D. 
niveus, D. marginatus, D. reticulatus in Almaty oblast were also described in previous 
published studies (141). Hence, our data reflects the recent results on the distribution of 
tick species in Almaty region.  
The collected ticks were investigated for the presence of TBEV RNA. In Kyzylorda all 
investigated RNA from all tick pools were negative for TBEV. This could be explained by 
the absence of the main vector of TBEV, the tick species I. persulcatus (61) Features of 
the natural landscapes might influence the dearth of I. persulcatus in Kyzylorda oblast. 
The landscapes such as deserts and steppes with lack of humidity are not favorable for 
I.persulcatus.(61). Despite recently the evidence of TBEV was also found in other tick 
species such as H. asiaticum, D. niveus and R. turanicus in Kazakhstan (61) we did not 
find TBEV RNA-positive pools of D. niveus, H. asiaticum and R. turanicus in Kyzylorda 
oblast.  
In comparison to Kyzylorda Oblast, in Almaty oblast, TBEV RNA was revealed in 
three tick species I. persulcatus, D. marginatus, and H. punctata. Previously published 
results by Japon demonstrated that ticks Dermacentor and Haemophisalis could be 
vectors of TBEV(143) 
Moreover, the findings of the study consistent with results of a previously conducted 
investigation in Kazakhstan; the evidence of TBEV infection in ticks species D. niveus 
and D. marginatus were demonstrated with TBEV antigen ELISA. These studies were 
engaged in Almaty and North Kazakhstan oblasts of Kazakhstan (144). 
 Following this, in our study, we can confirm that the endemicity of TBEV in ticks 
depends on the prevailed tick species I. persulacatus  
The MIR among positive tick species of I. persulcatus, D. marginatus, and H. 
punctata were 15.4%, 2%, 0.22% respectively; thus a higher MIR was detected in the 
regions of Almaty oblast in I. persulcatus. The MIR in Talgar, Tekeli and 
74 
 
Yenbekshikazakh regions of Almaty oblast are 4.35%, 2.82%, and 1.4% respectively. 
Only limited data on the TBEV MIR in ticks of investigated areas in Almaty oblast is 
available. Nevertheless, the MIRs in our study reflect the prevalence of TBEV in ticks in 
endemic regions in bordering countries. The prevalence in ticks ranged between 0.5% 
and 10.2% in Siberia (145) and 1.6% and 1.3% in Mongolia (146) (54). According to 
previous studies based on antigen detection with direct hemagglutination reaction 
conducted in Kazakhstan in 1970 the prevalence of TBEV in ticks reached 30% (63).  
In this project study we have used rt-RT-PCR. The MIR was up to 5%. It was 
explained that diagnostics methods were different. Previously used methods of 
investigation based on antigen detection with direct hemagglutination reaction or 
antigen ELISA. These methods have lower specificity than the real-time RT-PCR we 
used in our study(47) (147). Moreover, it was revealed that it has also higher sensitivity 
than conventional RT RT-PCR. It could be affected by amplification of shorter fragment 
(approximately 68 nt) in real time RT-PCR than amplification of longer fragment 
(approximately 1687 nt) in conventional RT-PCR(145) However, we could not exclude 
the fact that primers did not match perfectly the sites of amplification. So, sequence and 
subsequent phylogenetic analyses of 15 samples from Tekeli, eleven samples from 
Talgar and four samples from Yenbekshikazakh regions classified our isolates as the 
Siberian subtype of TBEV (figure 6). Comparisons of E gene of Siberian and Far 
Eastern subtype revealed that the virus strains from Tekeli are located within the 
Vasilchenko lineage of Siberian subtype and the strains from Talgar and 
Yenbekshikazakh are located within the Baltic lineage of the Siberian subtype. The 
comparison of the E gene sequences of our samples from Tekeli revealed highest 
similarities with the virus strain Almaarasan(60) which also was isolated in Almaty 
Oblast. Eleven virus sequences from Talgar and four from Yenbekshikazakh are closely 
related to the strain Buzuchuk and belong to the same lineage (148). Buzuchuk is an 
area in Kyrgyzstan close to the border of Kazakhstan. The Tekeli samples and 
Almaarasan from Almaty belong to the western cluster of Siberian subtypes because 
they are closely related to this cluster whereas the strains from Talgar and Buzuchuk 
are related to strains from Eastern Siberia. According to the data we got in our study we 
can hypothesize that strains could be distributed by birds more than 20 bird species are 
cross-border. These birds species could nest in Kyrgyzstan and fly to Kazakhstan and 
vice-versa (149) (150). Animals or along manmade routes like motorways or railways 
from the North to the South as an example the route from Siberia to China or Pakistan 
through Kazakhstan or vice versa (151). An important role of the strain distribution could 
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play bird migration. It has already shown in several studies that birds are able to carry 
the ticks over long distances (57) (152)(153)(154)(155). In Kazakhstan, during the last 
years due to the bird migration of birds the geographic borders of the bird fauna was 
changed. Some birds in the 50s of last century were only seen at the borders of the 
Southern Part of Kazakhstan, but now they became the main bird species over the 
whole territory (149) that could be a reason of spreading TBEV. Following this, since 
2017 the cases of TBEV has been registering in the North part of Kazakhstan. The role 
of animals is also a significant factor in TBEV distribution. Further ticks parasitize on 
mammals and could be carried by them by animal transports and transport the TBEV 
infected ticks into not endemic areas (156). 
 
6.1.2  The investigation of CCHFV in ticks 
The second question of this thesis was to look at CCHFV in ticks.  Any CCHFV positive 
pools were found in Almaty and Kyzylorda oblast. The negative pools for the CCHFV 
RNA presence in Almaty oblast could be explained by not endemic area for CCHFV and 
absence the main vector of CCHFV ticks spp. Hyalomma(61). 
 
6.1.3 Seroepidemiological study of TBEV infections. 
One of the major aims of this project study was to know the proportion of TBEV 
seropopositive patients among the patients who suffer from fever of uknown origin. 
Clinical presence of TBE could vary and manifestate with unspecific symptoms as fever 
to fatal neurological disorder (25). Hence the paired sera of 802 patients were screened 
for the presence of antibodies against TBEV.  
 The seroprevalence of TBE ranged between endemic Almaty oblast and not 
endemic Kyzylorda oblast, 1.9 % and 0.25 % respectively. In bordering Mongolia, 
serological investigations revealed approximately the same percentage of antibodies 
against TBEV in human samples (Selenge 5.1%, Bulgan 0.9%) (166).  
In Almaty oblast, we have found 1.24 % of IgG against TBEV that could be 
considered as the evidence of recent infection or immunity because of vaccination. 
 The questionnaire did not include a question over a conducted vaccination against 
TBE. However, I cannot claim that the IgG seropositivity is an outcome of vaccination 
against TBEV as an only limited part of the population in Kazakhstan is vaccinated 
against TBEV according to the Kazakh order number 562 of October 1, 2013, on 
Vaccination against Tick-borne Encephalitis (https://egov.kz/cms/ru/law): preventive 
immunization is performed to contingent of the population, which includes persons of 
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any profession whose work is connected with staying in the natural focus of tick-borne 
encephalitis. Therefore most of the Kazakh population is not vaccinated against TBEV.  
 Moreover according to some studies TBE could manifestate only with fever (26). During 
our project study we revealed only five patients among 18 seropositive who had 
meningeal symptoms. All patients suffered from temperature and they were not 
diagnosed as TBE. This gives the thought that in general most of TBE cases remain 
unregistered as patients often have only mild or no symptoms. 
 Also, we revealed 0.75% of patients with IgM antibodies against TBEV in Almaty 
oblast and 0.47% (two patients) in Kyzylorda oblast. Hence, the results of the 
serological investigation of TBEV demonstrates that the seroprevalence of in Almaty 
oblast is higher than in Kyzylorda oblast.  The findings of IgM antibodies against TBEV 
show evidence of acute infection. If in the case of Almaty oblast it could be expected as 
Almaty oblast is endemic for TBEV(61) (145)(10)., but the findings of acute TBEV 
infection in Kyzylorda oblast is a casuistry. However, the findings in Kyzylorda oblast of 
two IgM TBEV positive samples indicate, that TBE should be considered more carefully 
in Kyzylorda oblast as this is so far not notified as an endemic oblast for TBEV. 
More detailed investigation of risk factors of these two cases revealed that both of 
them have often contact with animals; no one noticed the tick bite or visited for TBEV 
endemic regions.  
Moreover, positive ELISA findings could be due to the cross-reactivity with other 
flaviviruses (117) (113) and require more deeply investigation and require confirmation 
by IFA or better neutralization assay. Due to the manufactures for ELISA virions 
inactivated with formalin are usedas antigens and these virions are directly coated on 
the plate. Although the manufactures give the high numbers over specificity, the results 
could be falsely positive because of cross-reactivity among flaviviruses. This is 
especially often reported in regions endemic for more than two flaviviruses e.g. 
Powassan, West Nile and Karshi viruses are endemic for Kazakhstan and 
Turkmenistan; in bordered Uzbekistan is evidence of circulation of Karshi and West Nile 
were described.  These viruses belong to the flavivirus genus and could be also a 
reason for fever and encephalitis(6) (49)(50). Hence, the cross-reactivity among 
flaviviruses and low specificity is a challenge for ELISA as previously, in experimental 
studies was investigated that due to the formalin-inactivated virions coated on the plate, 
the specificity could be decreased. Formalin-inactivation alter the Protein E, it leads to 
the formation of covalently cross-linked protein E oligomers and therefore change the 
specific epitopes and affects the reactivity of antibodies (51) 
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However, the positive TBE IgM samples in Kyzylorda oblast could be true TBE 
findings as we confirmed all positive samples with IFA. On the one hand these positive 
samples of TBE from Kyzylorda  could be the evidence of reactivation of semi-desert 
foci of TBEV, that were found in the 70s during the virological investigations of semi-
desert territories of the southern parts of Kazakhstan (145)(187)(188). But on the other 
hand TBEV carrying ticks could be transported with birds or animal from TBEV  
endemic region in non-endemic regions (152)(156)  
 
6.1.4  Seroepidemiological investigation of CCHF infections  
Clinical manifestation of CCHF varies from unspecific symptoms such as FUO to fatal 
hemorrhagic fever (73)(157). FUO is a significant public health issue as it is seldom 
adequately diagnosed and therefore the treatment of patients is insufficient 
(158)(2)(159)(1). Our study gives serological and molecular evidence that asymptomatic 
forms of CCHF are high in patients with FUO investigated in Kazakhstan. Kyzylorda is a 
well-known endemic region for CCHFV (127)(160)(61). However, our results show that 
asymptomatic CCHFV infections with mild and not specific symptoms also circulate in 
the non-endemic Almaty oblast. The rate of seropositivity and the symptoms correspond 
with those previously reported for CCHFV-endemic regions in the Balkans or 
Africa.(157)(161)(162)(158)(163)(164)(165). These findings are consistent with previous 
studies, which also found that, in a certain proportion of patients, the clinical 
manifestation of CCHF in endemic countries can appear without specific symptoms, so 
only with fever(165). Moreover, in a classification of clinical form of CCHF by 
Leshinskaya (1970) adopted in Kazakhstan a non-hemorrhagic form of CCHF takes 
place also. Some previous studies based on an indirect hemagglutination test for 
antigen detection and compliment fixation test for antibody detection were conducted in 
Kazakhstan in 1980ies. He it was shown that non-hemorrhagic forms of CCHFV could 
appear and reach up to 17% prevalence in CCHFV endemic regions (128).  
However, in this work four patients were IgM positive and in three of these the viral 
RNA was detected from patients from Kyzylorda oblast. So, the mild atypical symptoms 
appeared not only in patients with recent evidence of infection but also in patients with 
the evidence of acute disease. Importantly, the unexpected IgM-positive samples from 
Kyzylorda, confirmed with PCR(106), corroborate the conjecture by Christova et al. that 
CCHF could appear as an asymptomatic infection(158). The big debates upon IgG 
seropositivity and possible clinical forms of CCHF, as some authors suggest that CCHF 
could have "a subclinical form" of the disease without any clinical symptoms and we 
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could find only the evidence of recent infection in a certain proportion of the 
population(163). 
The CCHF ELISA was conducted by “Vector-Best” Kit. The “Vector-Best” 
manufacture gives around 100% of sensitivity www.vector-best.ru. However, according 
to some studies the sensitivity of IgM and IgG "Vector-best" is much less, 87.8% and 
80.4% respectively (113). However, according to the study, the given sensitivity 100% 
could match the Kazakh samples as "the Vector-Best" manufacture used the region 
oriented strains (166).  
The positive CCHF samples were not tested by e.g. a confirmatory IFA - in 
comparison to the serological investigation of TBEV. But this was not needed as 
CCHFV RNA was detected in positive IgM samples. 
     The evaluation of independent risk factors and CCHFV seropositivity shows that the 
rate of CCHFV seropositivity is higher in people with a history of contact with animals 
and occupations linked to the animal husbandry (p<0.05). Previous studies also 
reported that people could be infected only in occasional contact with livestock. The 
overlap of CCHFV seroprevalence in animals could lead to the incidence in human 
(167)(84). It was revealed that mostly all animals with the exception of pigs lead to an 
increased prevalence of CCHFV seropositivity, however the effects are only statistically 
significant for cattle and horses. This could be explained that most of the population in 
the investigated cohort are engaged in animal husbandry. Kazakhstan is an agro-
industrial country, and the animal husbandry is a traditional branch of agriculture 
(www.articlekz.com). It was also revealed that an independent risk factor as a tick bite 
unrelated to the seropositivity. It could be explained that usually people could not feel a 
tick bite or could manifest with different skin lesions (168) (see table 15). The risk 
factors that increased CCHFV seropositivity reflect the risk factors for CCHFV described 
in previous studies. For example the contact with animals and occupation as a farmer 
(animal husbandry) significantly increase the CCHFV seropositivity (169)(170). Although 
previous studies describe that tick bites is a risk factor that significantly increases 
seropositivity, we were not able to reveal the association of the CCHFV seropositivity 
with tick bites during this study (169)(171)(172)(84)(119). 
 
6.1.5  Molecular investigation of positive sera for CCHFV 
 The results of the sequence of S and L segments of two CCHFV-posiitve samples 
from Kyzylorda show that they clustered within the CCHFV Asia 2 subgroup, whereas 
the sample Shieli 26 is within the CCHFV Asia 1 group. Previous studies report that 
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these two subgroups are present in Kazakhstan(173). Although the close relation 
between the S segment phylogeny and territory is reported and the territory of 
Kazakhstan does not adjust to any countries with circulation Asia1 subgroup. Our 
findings support data previously described in Barry Atkinson thesis, 2016, that there is 
evidence of circulation of different CCHFV subgroups on the same territory (6). Despite 
in previous papers 12 sequences were described in Kazakhstan and they belong to 
Asia 1, Asia 2 and Africa 3 subgroups, never the reassortant of the CCHF virus was 
described previously. This study revealed that the sample Shieli 26 contains a 
recombinant belonging to Asia 1 subgroup; in detail the S segment sequence analysis 
of three (Sh26, Kyz43, Kyz121) clustered within Asia 2 group and one sample (Sh26) is 
reassorted genotype Asia 2 in S segment and Asia 1 in L segment. The recombination 
is a way of RNA viruses to generate the genetic assortment and refer to some 
hypothesis it is a way of virus defense to circumvent the immune system(174). The 
recent study shows that the virus migration even in local distance plays a statistically 
significant role in virus transmission and virus recombination (175)(176). Therefore, bird 
migration could play a significant role in the transmission of the virus and explain the 
presence of Asia 1 subgroup in Kyzylorda oblast (65)(175)(176). 
 
6.2 Limitations of project study 
 
6.2.1. Tick study 
Despite the previously conducted training with specialists of the organizations who 
collected the ticks and delivered them from the remote areas, the ticks that we 
investigated in some cases were delivered with violation of the delivery regime, 
especially from the remote areas as Kyzylorda oblast. The violation of the delivery 
regime affected the results of molecular investigations in case of RNAs investigation, as 
RNAs are very sensitive and could be destroyed very quickly. Also, in some cases, the 
critical data as coordinates of tick collection were wrongly marked. 
  
 6.2.2. Serological study  
 Despite the conducted training of medical facilities to collect the blood from the, 
collecting two pairs of sera and patients support in filling the questionnaires, not all 
samples met the criteria to be included in the study. The limitation of this study was the 
collection of data. Due to the lack of continuity among medical organizations and the 
governing bodies, scientific institutions the collection of blood data were difficult. The 
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planned time for blood collection was prolonged from 1 year to 2.5 years. Hence after 
this time, 950 sera samples were delivered for investigation, but only 802 serum pairs 
met the criteria of inclusion and could be investigated further for TBEV and CCHFV 
One of the significant limitations is a cross-sectional study design of this performed 
seroepidemiological study. A cross-sectional study has its intrinsic susceptibility to bias 
because of misclassification due to recall biases and due to low response. Hence some 
possible influences on seropositivity as the living conditions, the possible contact with 
animals, tick bites were not measured impartially. Moreover, due to the cross-sectional 
design of the study, there was a limitation of its inherent ability to make the cause-effect 
relationship (177). 
 
6.2.3.Molecular methods of investigation 
Due to the lack of data on previously circulated TBEV subtypes in Kazakhstan, the 
selection of adequate primers to succeed to get the E-gene for molecular 
characterization of the TBEV strains was undertaken. The primers and protocols for 
target E gene RT-PCRs were further developed in this study and updated.  
During the molecular investigation of CCHFV, the protocol of the RT-PCR was 
updated. The previous protocol was suggested by Atkinson et al. 2012 by applying the 
LightCycler 2.0 and LightCycler 480 machines (Roche Diagnostics Corporation, 
Indianapolis). During the study, the protocol was optimized on Rotorgen and Qiagen kit 
(Hilden, Germany). Due to optimization, many false positive results were detected. 
Troubleshoot was the confirmation of all positive samples by running in agarose 1.5% 
gel and GelRed. 
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7 CHAPTER 7 
7.1 Conclusion 
In summary, I described in detail data regarding TBEV circulation in Almaty oblast in 
Kazakhstan. For the first time, I gave the information about the MIR of TBEV in ticks in 
endemic (Almaty) oblast being up to 4.4%. Moreover, for the first time, the subtype of 
circulating TBEV was determined; in detail, the sequence analyzing revealed that 15 
Tekeli samples belong to Vasilchenko lineage, four Yenbekshikazakh samples and 11 
samples of Talgar samples belong to the Baltic lineage of Siberian subtype.   
Also, for the first time in Kazakhstan was conducted the seroepidemiological study on 
the investigation of CCHFV and TBEV. The interesting findings were the detection of 
acute TBE in patients with fever of unknown origin in not endemic for TBE oblast. This 
data gave a thought to investigate further TBEV circulation in not endemic oblasts and 
get the full genome sequence of TBEV. Hence, this project study was a basis for further 
investigations in this field. Currently is another Ph.D proposal discovering the question 
of circulation and clinical aspects of TBE in not endemic for TBE Akmola oblast; In detail 
ticks and human samples are investigated from Akmola oblast.  
Moreover, for the first time, in Kazakhstan was described that acute CCHF could 
appear as asymptomatic infection in a certain proportion of the population in the 
endemic region. Molecular methods of investigation proved this finding. Four patients 
were IgM positive and in three of these the viral RNA was detected from patients from 
Kyzylorda oblast. So, the mild atypical symptoms appeared not only in patients with 
recent evidence of infection but also in patients with the evidence of acute disease. 
Therefore, these IgM positive patients were unexpected and findings during the study. 
Also, for the first time, we detected the recent CCHF infection in patients with fever in 
not endemic Almaty oblast. For the first time, we described the information about the 
distribution of CCHF and the prevalence of CCHF in Kazakhstan. Also, for the first time, 
TBE was investigated in endemic and not endemic oblasts (areas). If in a case of 
endemic Almaty oblast, it was expected the proportion of TBE positive patients up to 2 
%, but for Kyzylorda oblast, it was a casuistry. Hence we are for the first time reported 
about the acute TBE cases (0.25%). The results of this project study show that the 
distribution of CCHF and TBE could be broader, and be the reason for FUO. FUO 
should be a significant aware for physicians who face with fever during the tick activity. 
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7.2 Recommendations 
According to the results of study projects the improvement of surveillance system 
over the CCHF and TBE is recommended. It is recommended to implement the 
molecular methods of investigation of vectors and in an investigation of TBE and CCHF 
suspicious cases among humans that were worked out during the project study. It is 
recommended to investigate other areas with suspicious cases as the distribution of 
these infections could be broader. Moreover, public health education over the 
transmission of these infections is also recommended. 
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Annex 3. Statement of Pre-release and contribution 
Two articles are part of this project study. The international journal of infectious 
diseases published one of them. The title of this published article is 
"Seroepidemiological and molecular investigations of infections with Crimean-Congo 
hemorrhagic fever virus in Kazakhstan."   
The second article titled “Epidemiological and Molecular investigations of TBEV in 
Kazakhstan give new insights in vectors and phylogeny” is being reviewed for the 
submission to Parasites and Vectors peer-reviewed journal.  
The Ph.D. candidate Karlygash Abdiyeva collected the sera samples and ticks for 
further investigation herself and with the help of trained specialists of medical facilities of 
target oblasts and Scientific Practical Center of Sanitary-Epidemiological expertise and 
Monitoring (SPCSEEM). All laboratory work and evaluation of results were done by the 
Ph.D. candidate under the close supervision of the direct supervisor. Moreover, Ph.D. 
candidate Karlygash Abdiyeva did the data evaluation and analyzing, wrote two articles 
under the close supervision of all supervisor. 
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Annex 6. Informed Consent Form 
“Study of Patients with Fever of unknown origin due to selected Infectious 
Diseases in five regions (oblasts) of Kazakhstan” 
You are being invited to join this research study because we want to find out if you 
have an acute infection with certain bacteria and viruses. It is possible to do a blood test 
to see if you have been exposed to these infections, either recently or long ago. After a 
person is exposed to a virus or bacteria, they produce substances called antibodies. 
Antibodies are proteins made by the body's natural defense system (immune system) to 
attack and destroy foreign substances, such as bacteria and viruses.  
These antibodies can remain in the blood of people for many years after exposure to 
the infection. This study is designed to measure antibodies against some infections.  
The infections to be studied include brucellosis, leptospirosis, leishmaniosis, 
meloidosis, glanders, borreliosis, erlichiosis, anaplasmosis, Q-fever, spotted fever, 
plague, anthrax, tularaemia,typhus group and scrub typhus group rickettsioses, tick-
borne encephalitis (TBE), West Nile fever, Dengue virus infections, Japanese 
encephalitis, California encephalitis, Sindbis virus infection, Tahyna virus infection, 
Congo-Crimean Hemorrhagic Fever (CCHF), sandfly viruses, hanta- and enterovirus. 
We are testing you to determine if you have an active infection with these bacteria or 
viruses.  
Purposes of this Study: 
1. To see how many hospitalized people in Kazakhstan have antibodies to the
infections mentioned above. 
2. To figure out risk factors associated with prior exposure to these infections
3. To aid in the development of future scientific research and developing preventative
programs and treatment of disease 
Eligibility for Participation: 
To join this study, you have a onging fever where the reason is not known for.   
You cannot join this research study if you are less than 15 years of age.  
Screening Procedures: 
If you agree to participate in this study, one of the study team members will ask about 
your understanding of the study and if you have any questions. They will make sure you 
are eligible to participate in the study. 
Collection of Samples: 
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We will draw approximately 20 ml (approximately four teaspoons) of blood from a 
vein in your arm twice: in the day of hospitalization and on 7-14 day of disease. We will 
also ask you some questions about the possibility that you have had a prior exposure to 
the infections to be studied. You will not have to do anything other than give blood and 
answer questions. As a volunteer you do not have to answer any question(s) about 
which you feel uncomfortable. 
Specimen Testing: 
Your blood will be tested for antibodies against the infections we mentioned earlier in 
the consent form. Testing could occur at the Bundeswehr Institute of Microbiology 
(InstMikroBioBw, Germany), at the SPC SEEM, in Kazakhstan, at the KazNMU 
(Kazakhstan) or even laboratories at other places in the world (see future testing 
section). T 
Test Results: 
We will not inform you of the results of the testing. It is important that you understand 
that a positive result may mean you had one of these infections in the past. It does not 
mean that you are infected now. Therefore, the results of these tests do not affect your 
current health status.  
Future testing: 
We would like to save some of your blood sample for future tests possibly at 
Kazakhstan and German laboratories, or possibly other laboratories in other countries. 
At the end of this form, you will have the opportunity to decide whether or not to allow us 
to do that. Because medical technology is changing rapidly, we cannot tell you with 
confidence what types of studies we might conduct. However, any future studies will be 
limited to research broadly related to the present research objectives. Any sample of 
your blood used for future testing will be labelled only with a study number and will not 
be linked to any of your personal information. You will not receive a report on any 
results that may come from future studies.   
Duration of Study: 
Your participation in this study will take approximately 20 minutes. If you agree to 
future testing, we will retain your blood sample at the SPC SEEM, the KazNMU and the 
InstMikroBioBw, for 10 years. If you do not agree to future testing, we will dispose of 
your blood sample at the end of the study. We will retain papers from the study and the 
data at the SPC SEEM, the KazNMU and the InstMikroBioBw for 10 years. 
Foreseeable Risks or Discomforts: 
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There are several small risks to participating in this study. There could be some 
discomfort associated with the needle stick for a blood draw. You could have swelling or 
bruising, and there is a small risk of infection at the site of the needle stick. Although 
most people have no infection or noticeable swelling, it cannot be prevented in all 
cases. In the majority of cases, such bruises will go away by themselves in 1 to 
2 weeks. A few people feel light-headed and may develop a fast heartbeat during blood 
collection. These symptoms can be halted by having you lay down and/or by stopping 
the procedure. Rarely, you may develop a blood clot at the site of the blood draw. The 
area around this blood clot can become red and painful. The bump associated with the 
blood clot can persist for many weeks. These are the risks of obtaining blood samples, 
but significant complications do not often occur. 
There is a small risk that your confidentiality may be breached. Measures to protect 
your personal information will be described in detail. 
Benefit to Subject: 
There is no direct medical/health benefit to you by participating in this study. 
However, this study may benefit the health of people in your community in the future. 
Circumstances of Withdrawal: 
Your participation is voluntary. You may withdraw from this study at any time without 
losing any benefits that you would otherwise have. Your participation may also be 
terminated without your consent if health conditions or other conditions occur that might 
be dangerous or detrimental to your health, you fail to comply with the procedures 
outlined in this informed consent, or the Sponsor terminates this study. 
Confidentiality of Volunteers: 
All data and medical information obtained about you, as an individual, will be 
considered privileged and held in confidence. You will not be identified by name in any 
published report or presentation of the results. The Kazakhstan authorities will receive a 
report containing grouped results, but will not be able to identify you individually. As part 
of their responsibility to oversee research and ensure protection of volunteers, the 
Kazakhstan authorities may inspect the records of this research. Regulatory groups in 
Kazakhstan and German Science Institutions may also inspect the records of this 
research. By signing this consent form, you agree to such inspection and disclosure. 
Complete confidentiality cannot be promised to volunteers because reporting 
information to appropriate medical or command authorities about your health may be 
required. Kazakhstan law requires us to ask for your permission to use your information 
for research. You can stop us from using your information at any time by contacting us 
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and asking us to stop. Signing the informed consent form you agree to participate in 
study. 
CONSENT for the Use of Your Samples for Future Studies: 
There is a possibility that the blood sample you are donating during this study may be 
used in other research studies and for other types of research tests. These tests may be 
performed possibly at the SPC SEEM, the KazNMU in Kazakhstan and the 
InstMikroBioBw in Germany, or possibly other laboratories in other countries. You will 
not be notified of future uses of your sample. Please indicate your willingness to permit 
this use of your donated sample by signing the appropriate statement:  
Sample can be stored for future use for up to 10 years 
Sample may be used in other research studies in the future
_______________________ 
Sample has to be used in the current study only. 
Sample cannot be stored for future use. _______________________ 
CONSENT for Participation in the Research Study: 
Your signature below indicates that you have read this informed consent document, 
the research study has been explained to you and your questions have been answered, 
and you agree to take part in this study. You will receive a copy of this signed form. 
___________________________________ 
Printed Name of Volunteer 
___________________________________ 
Permanent Address of Volunteer 
___________________________________ 
Printed Name of Person Conducting the  
Informed Consent Discussion 
___________________________________ ___________________ 
Signature of Person Conducting the  Date (dd/mm/yyyy) 
Informed Consent Discussion 
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___________________________________ 
Printed Name of Witness (if applicable) 
___________________________________ ___________________ 
Signature of Witness (if applicable)  Date (dd/mm/yyyy) 
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Informed Consent Document for parents of children (15 years and older) 
participating in 
“Study of Patients with Fever of unknown origin due to selected Infectious 
Diseases in five regions (oblasts) of Kazakhstan” 
Children with acute and current fever may have an acute infectious disease with 
certain bacteria and viruses. For these reasons, we want to test the blood of your child. 
We can with this test see if your child has been exposed to these infections, either 
recently or long ago. After a person is exposed to a virus or bacteria, they produce 
substances called antibodies. Antibodies are proteins made by the body's natural 
defense system (immune system) to attack and destroy foreign substances, such as 
bacteria and viruses. These antibodies can remain in the blood of people for many 
years after exposure to the infection. This study is designed to measure antibodies 
against some infections in children between 15 and 18 years. 
The infections to be studied include brucellosis, leptospirosis, leishmaniosis, 
meloidosis, glanders, borreliosis, erlichiosis, anaplasmosis, Q-fever, spotted fever, 
plague, anthrax, tularaemia,typhus group and scrub typhus group rickettsioses, tick-
borne encephalitis (TBE), West Nile fever, Dengue virus infections, Japanese 
encephalitis, California encephalitis, Sindbis virus infection, Tahyna virus infection, 
Congo-Crimean Hemorrhagic Fever (CCHF), sandfly viruses, hanta- and enterovirus. 
We are testing your child to determine if it has an active infection with these bacteria or 
viruses.  
Purposes of this Study: 
1. To see how many hospitalized children in Kazakhstan have antibodies to the
infections mentioned above. 
2. To figure out risk factors associated with prior exposure to these infections
3. To aid in the development of future scientific research and developing preventative
programs and treatment of disease 
Eligibility for Participation: 
To join this study, your child should have an ongoing fever where the reason is not 
known for.  
As rule, a child is legally unable to provide informed consent. For this reason before 
testing your child (<15 years) for mentioned above infections You (Parent(s)/legal 
guardian) have to sign an Informed Signed Form. You have the right to refuse to sign 
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this form without any justification nor prejudice in regard to services provided to him by 
the hospital. According to Kazakh ethics rules and Good Clinical Practice for the 
protection of people rights, a child cannot be included in this project without the parent’s 
or his legal guardian’s signature. Copies of the Informed Consent Form together with 
this Information Notice will be handed to you for your record if you accept that your child 
participates in this project.  
Screening Procedures: 
If you agree that your child participates in this study, one of the study team members 
will ask about your understanding of the study. If you have any questions, they will 
make sure that your child is eligible to participate in the study. 
Collection of Samples: 
We will draw approximately 20 ml (approximately four teaspoons) of blood from a 
vein in the arm of your child twice: in the day of hospitalization and on 7-14 day of 
disease. We will also ask you and your child some questions about the possibility that 
you have had a prior exposure to the infections to be studied. Your child will not have to 
do anything other than give blood and with your help to the answer questions. As a 
volunteer your child does not have to answer any question(s) about you or your child 
feel uncomfortable. 
Specimen Testing: 
The blood sample of your child will be tested for antibodies against the infections we 
mentioned earlier in the consent form. Testing could occur at the Bundeswehr Institute 
of Microbiology (InstMikroBioBw, Germany), at the SPC SEEM, in Kazakhstan, at the 
KazNMU (Kazakhstan) or even laboratories at other places in the world (see future 
testing section).  
Test Results: 
We will not inform you and your child of the results of the testing. It is important that 
you understand that a positive result may mean your child had one of these infections in 
the past. It does not mean that your child is infected now. Therefore, the results of these 
tests do not affect the current health status of your child. 
Future testing: 
We would like to save some of your child blood sample for future tests possibly at 
Kazakhstan and German laboratories, or possibly other laboratories in other countries. 
At the end of this form, you will have the opportunity to decide whether or not to allow us 
to do that. Because medical technology is changing rapidly, we cannot tell you with 
confidence what types of studies we might conduct. However, any future studies will be 
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limited to research broadly related to the present research objectives. Any sample of 
your blood used for future testing will be labelled only with a study number and will not 
be linked to any of your personal information. You and your child will not receive a 
report on any results that may come from future studies.  
Duration of Study: 
The participation of your child in this study will take approximately 20 minutes. If you 
agree to future testing, we will retain blood sample of your child at the SPC SEEM, the 
KazNMU and the InstMikroBioBw, for 10 years. If you do not agree to future testing, we 
will dispose of this blood sample at the end of the study. We will retain papers from the 
study and the data at the SPC SEEM, the KazNMU and the InstMikroBioBw for 10 
years. 
Foreseeable Risks or Discomforts: 
There are several small risks to participating in this study. There could be some 
discomfort associated with the needle stick for a blood draw. Your child could have 
swelling or bruising, and there is a small risk of infection at the site of the needle stick. 
Although most people have no infection or noticeable swelling, it cannot be prevented in 
all cases. In the majority of cases, such bruises will go away by themselves in 1 to 2 
weeks. A few people feel light-headed and may develop a fast heartbeat during blood 
collection. These symptoms can be halted by having you lay down and/or by stopping 
the procedure. Rarely, your child may develop a blood clot at the site of the blood draw. 
The area around this blood clot can become red and painful. The bump associated with 
the blood clot can persist for many weeks. These are the risks of obtaining blood 
samples, but significant complications do not often occur. 
There is a small risk that your child confidentiality may be breached. Measures to 
protect his/her personal information will be described in detail. 
Benefit to Subject: 
There is no direct medical/health benefit to your child by participating in this study. 
However, this study may benefit the health of people in your community in the future 
Circumstances of Withdrawal: 
The participation of your child in this study research is voluntary. Your child may 
withdraw from this study at any time without losing any benefits that you would 
otherwise have. The participation of your child may also be terminated without your 
consent if  your child health conditions or other conditions occur that might be 
dangerous or detrimental to his/her health, you or your child fail to comply with the 
procedures outlined in this informed consent, or the Sponsor terminates this study. 
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Confidentiality of Volunteers: 
All data and medical information obtained about your child, as an individual, will be 
considered privileged and held in confidence. Your child will not be identified by name in 
any published report or presentation of the results. The Kazakhstan authorities will 
receive a report containing grouped results, but will not be able to identify your child 
individually. As part of their responsibility to oversee research and ensure protection of 
volunteers, the Kazakhstan authorities may inspect the records of this research. 
Regulatory groups in Kazakhstan and German Science Institutions may also inspect the 
records of this research. By signing this consent form, you agree to such inspection and 
disclosure. Complete confidentiality cannot be promised to volunteers because 
reporting information to appropriate medical or command authorities about your child 
health may be required. Kazakhstan law requires us to ask for your permission to use 
your information for research. You can stop us from using your child information at any 
time by contacting us and asking us to stop. Signing the informed consent form you give 
the permission and agreement to your child to participate in study. 
CONSENT for the Use of your child blood samples for Future Studies: 
There is a possibility that the blood sample your child is donating during this study 
may be used in other research studies and for other types of research tests. These tests 
may be performed possibly at the SPC SEEM, the KazNMU in Kazakhstan and the 
InstMikroBioBw in Germany, or possibly other laboratories in other countries. You and 
your child will not be notified of future uses of your sample. Please indicate your 
willingness to permit this use of your child donated sample by signing the appropriate 
statement:  
Sample can be stored for future use for up to 10 years 
Sample may be used in other research studies in the future
_______________________ 
Sample has to be used in the current study only. 
Sample cannot be stored for future use. _______________________ 
CONSENT for Participation in the Research Study: 
Your signature below indicates that you have read this informed consent document, 
the research study has been explained to you and your questions have been answered, 
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and you give the permission to your child to take part in this study. You and your child 
will receive a copy of this signed form. 
____________________________________________________ 
Printed Name of Volunteer (a pediatric subject) 
_____________________________________________________ 
Printed Name of parent’s(s)/ a legal guardian 
_____________________________________________________ 
Permanent Address of Volunteer (a pediatric subject)  
___________________________________ 
Printed Name of Person Conducting the  
Informed Consent Discussion 
___________________________________ ___________________ 
Signature of Person Conducting the  Date (dd/mm/yyyy) 
Informed Consent Discussion 
___________________________________ 
Printed Name of Witness (if applicable) 
___________________________________ ___________________ 
Signature of Witness (if applicable)  Date (dd/mm/yyyy) 
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Annex 7 Questionnaire 
General Information – The following questions should be filled by the interviewer 
1.1 MODULE 1 
SOCIODEMOGRAPHICS 
1.2 Hospital ID number |__|__|__| 
1.3 Date of Interview 
(DD.MM.YYYY) |__|__| . |__|__| . |__|__|__|__| 
  Day      Month         Year 
1.4 Participant ID |__|__|__|__|__|__|__| 
1.5 Sex of participant 1 
2 
Male 
Female 
1.6 Name of Study Site 1 
2 
3 
4 
5 
Almaty region 
East Kazakhstan 
North Kazakhstan 
West Kazakhstan 
Kyzylorda  
Start of Interview – The following questions should be asked to the patient 
1.7 When were you born? 
(INT: Enter “99” if day 
and/or month is unknown and 
9999 if year is unknown) 
|__|__| . |__|__| . |__|__|__|__| 
  Day     Month          Year 
1.8 How old are you now? 
(Enter “999” for declined to 
answer) 
|__|__|__| 
Age in years 
1.9 What is your present 
marital status?  
1 
2 
3 
4 
5 
6 
7 
Single 
married 
Not married, living with permanent partner 
Separated/divorced 
Widowed 
Declined to answer  
Other (please specify) 
__________________________ 
1.1
0 
Where were you born? 
(country of birth) 
1 Kazakhstan 
2 Kirgistan 
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3 Usbekistan 
4 Other country (please specify): 
__________________________ 
1.1
1 
In which oblast of 
Kazakhstan were you born? ____________________________ 
1.1
2 
In which City/Town/Village 
do you live?  ____________________________ 
1.1
3 
Since when have you been 
living in this 
City/Town/Village? 
(Enter “999” for declined to 
answer/don’t know) 
1 Always lived in this place 
2 Since    |__|__|__|  Years 
1.1
4 
Have you done any trips 
from your place of residence 
within the last month? 
1 
2 
No 
Yes (please specify where): 
__________________________ 
1.1
5 
Have you done a trip into 
nature? 
1 
2 
No 
Yes (please specify where, when and how 
often): 
__________________________ 
__________________________ 
__________________________ 
__________________________ 
1.1
6 
Have you had contact with 
wild animals?  
1 
2 
No 
Yes (please specify): 
____________________________ 
1.1
7 
Have you been biten by 
ticks, mosquitoes, insects or 
wild animals within the last 
month? 
1 
2 
No 
Yes (please specify) 
____________________________ 
MODULE 2 EDUCATION AND WORK 
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2.1 What is your highest 
level of education? 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Still in school (pupil/student) 
Still in college (student) 
Still in academy/institute/university (student) 
Secondary education 
Secondary education unfinished 
Any vocational education 
Vocational education unfinished 
Any higher education 
Higher education unfinished 
Have no formal education 
Declined to answer/Don’t know 
2.2 What is your current 
occupation? 
Full
-time 
Part-
time 
 (Multiple answers 
allowed. For each single 
answer please ask If the 
work is done full-time or 
part-time) 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Pupil/Student (full-time)  
Farmer/Peasant/Farmworker (plants) 
Farmer/Peasant/Farmworker (animal)  
Farmer/Peasant/Farmworker (forestry) 
Keeping the house (housewife) 
Unskilled Labourer 1 __________________ 
Skilled Labourer 2     __________________ 
Local or long distance driver  
Administrative or academic professional 3 
Businessman/woman 
Nurse/Physician/Clinician/Pharmacist 
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6 
7 
8 
9 
10 
11 
12 
13 
14 
11 
12 
13 
14 
Unemployed 
Declined to answer 
Other (please specify) 
______________________________ 
1 please specify 
2 factory worker, mechanic, painter, welder, carpenter, 
dressmaker, technician… 
3 secretary, bank clerk, teacher, pastor, surveyor, lawyer, 
accountant, engineer, labworker, scientist… 
2.3 How long have you 
been working in your 
current occupation? 
(Enter “99” for 
declined to 
answer/don’t know) 
  |__|__| 
  Years 
2.4 How often do you 
normally work in the 
gardens and fields? 
(plant cultivation) 
1 
2 
3 
45 
Yes, always/daily 
Yes, often 
Yes, occasionally 
No, never 
2.5 Can you read a letter 
or newspaper easily, 
1 
2 
Easily 
With difficulty 
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with difficulty, or not at 
all? 
3 
4 
Not at all 
Declined to answer 
2.6 What is the total 
cash income of your 
household per year? 
1 
2 
3 
4 
Low (below 900,000 tenge, 5,000 $ per year) 
Medium (900,000 – 1,800,000 tenge, 5,000 - 10,000 
$ per year) 
High (> 1,800,000 tenge (>10,000 $ per year) 
Decline to answer/do not know 
Module 3 LIVING AND HOUSING 
3.1 How many people 
do normally eat 
together in your 
household? 
(Enter “99” for 
declined to 
answer/don’t know) 
 |__|__| 
     Number 
3.2 What type is your 
flat/house? 
1 
2 
3 
4 
Well-equipped city apartment 
Poorly equipped city apartment 
Private well-equipped house 
Poorly equipped house 
Other (please specify): 
_____________________________________ 
3.3 Where do you store 
your bulk products 
(flour, sugar, rice, 
etc…)? 
1 
2 
3 
In bags 
In casks 
Other (please specify) 
______________________________________ 
3.4 From where do you 
get your water? 
3 
4 
5 
5 
city water pipe 
rural water pipe 
blow well 
river 
3.5 Did you drink raw 
milk directly from the 
animal or eat raw milk 
1 
2 
No 
Yes 
If yes, from which animal? 
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products without 
pasteurization? 
______________________________________ 
MODULE 4: livestock 
4.1 What kind of livestock 
does your household own 
and how many of each 
species?  
(if the real number is 
unknown, please estimate – 
Enter “000” for animal if 
none and “999” for don’t 
know) 
Cattle    |__|__|__| Number 
Horse      |__|__|__| Number 
Goats    |__|__|__| Number 
Sheep   |__|__|__| Number 
Pigs       |__|__|__| Number 
Poultry         |__|__|__| Number 
Cats/Dogs    |__|__|__| Number  
other: ________________________________ 
4.2 Did the animals have any 
kind of disease? 1 
Yes 
If yes, which kind of animal?  
________________________________ 
2 
No 
4.3 Which symptoms did 
you notice? 1 
2 
3 
4 
5 
Unusual movement 
Respiratory symptoms 
Gastroenterological symptoms 
Lesions 
Others, please specify:  
________________________________ 
Don’t know 
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6 
4.4 Did you notice an 
unusual high number of 
animal deaths? 
1 
No 
2 
Yes 
If yes, which animal?  
_________________________________ 
4.5 Do you have contact 
with died animals? 1 
2 
No 
Yes 
If yes, which animal?  
_________________________________ 
4.6 How often do you have 
direct contact to the 
following animals?  
(“Contact” means 
working with these animals, 
milking, slaughtering, 
handling raw meat), but 
NOT eating cooked meat 
Always/daily Most 
of the 
times 
Rarely Never 
Cattle? 1 2 3 4 
Horse 1 2 3 4 
Goats? 1 2 3 4 
Sheep 1 2 3 4 
Pigs? 1 2 3 4 
Cats/Dogs 1 2 3 4 
Poultry? 1 2 3 4 
4.7 Do you handle raw 
meat? 
(slaughtering, 
butchering, preparing for 
cooking) 
1 
2 
3 
4 
Yes, always 
Yes, most of the times 
Yes, but rarely 
No, never 
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4.8 How often do you 
see/notice rats or mice (or 
bat poop) 
1 
2 
3 
4 
Always 
Most of the times 
Rarely 
Never 
4.9 How often do you have 
to kill them in the house? 1 
2 
3 
4 
Always 
Most of the times 
Rarely 
Never 
4.10 Do you have bird nests 
in the roof? 1 
2 
3 
Yes 
No 
Don’t know 
4.11 Do bats live in your 
house or in trees around 
your house? 
1 
2 
3 
Yes 
No 
Don’t know 
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MODULE 5: VECTOR HABITAT FACTORS 
5
.1 
Where is your house 
located, in urban or rural area? 
1 
2 
Rural area 
Urban area 
5
.2 
What kind of ground is 
around your residence?  
1 
2 
3 
Tarmac 
Sand 
Dirt 
5
.3 
How does the vegetation 
around your residence look 
like? 
(Multiple answers allowed 
– mark all that apply.)
1 
2 
3 
4 
5 
6 
7 
Dense plantation/forest 
Larger grass fields 
Occasional bush agricultural fields 
Swamp  
Lake 
Forest 
Others (please specify):  
5
.4 
Is there sometimes 
standing water close to your 
residence? 
(Multiple answers allowed) 
1 
2 
3 
4 
5 
6 
7 
7 
Yes: 
Puddles after heavy rain 
Containers for collecting water 
Lake 
stream 
Gully in urban area 
No, never 
Don’t know 
5
.5 
How many months per year 
is that water around your 
residence? 
|__|__| 
Number of month 
MODULE 6: CLINICAL SYMPTOMS 
6.
1 
Beginning of the 
symptoms 
1 
2
> 5 days ago 
< 5 days ago 
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6.
2 
Please indicate below 
which symptom(s) you have: 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
Fever 
Headache 
Neck pain (meningism) 
Weakness of muscels or joints 
Muscle pain or recurrent cramps 
Pain on swallowing 
Joint pain 
Stomach/abdominal pain/cramps 
Back pain 
Earache 
Cough 
Difficulties in speaking, hearing or seeing 
Seizures/Epilepsy 
Difficulties in breathing,  
Rapid breathing 
Sore threat 
Congestion of nose 
Enlarged lymph nodes 
Icterus 
6.
3 
Body temperature 
(ear measurement) 
1 
2 
< 37.5°C 
> 37.5°C 
If body temperature is > 37.5°C, than fill out 6.4 
6.
4 
Duration of high body 
temperature 
1 
2 
< 3 days 
3 days and more 
6.
5 
Blood pressure 1 
2 
Normal 
Hypotension 
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3 Hypertension 
6.
6 
Pulse rate 1 
2 
3 
< 80 
80 – 100 
> 100 
6.
7 
Skin conditions 1 
2 
3 
4 
Exanthema 
Ulceration 
Edema 
Others (please specify) 
__________________________________ 
6.
8 
Stool 1 
2 
3 
4
Diarrhoea 
Blood in stool 
Bright stool 
Others (please specify) 
__________________________________ 
6.
9 
Urine 1 
2 
3 
4 
5 
Blood in urine 
Pain on urinating 
Dark urine 
Low urine volume 
Others (please specify) 
__________________________________ 
6.
10 
Medications 1 
2 
3 
4 
Antipyretics 
Antirheumatics 
Antibiotics 
Others (please specify) 
___________________________________ 
6.
11 
Duration of therapy __ Days 
6.
12 
Similar illnesses in the 
family or in the surrounding 
1 
2 
Yes 
No 
